 
 
 
 
Protocol 851655 – The SENSation Study  
OC-01 (varenicline  solution) Nasal Spray    
 
SENSation Study Revision 04/2023  
 

  
Protocol 851655 - The SENSation Study   
OC-01 (varenicline solution) Nasal Spray  Page 2 of 67 
 
 
Confidential and Proprietary Information of  Oyster Point Pharma  
 
CLINICAL RESEARCH PR OTOCOL  
 
INVESTIGATIONAL 
PRODUCT(S) : 
 OC-01 (varenicline solution) Nasal Spray  
STUDY 
NUMBER(S):  IRB 
Number  851655  
Other 
Protocol 
Identifiers   N/A 
PROTOCOL(S) TITLE:  A Single -arm Investigator Initiated Study to Evaluate the 
Efficacy of OC -01 (varenicline solution) Nasal Spray on signs 
and symp toms of Dry Eye D isease in subjects with Sj ogren’s 
Syndrome  
 
NUMBER:  [STUDY_ID_REMOVED]  
REGULATORY 
SPONSOR:  
 "[Insert Sponsor Name and Address Here]"  
FUNDING SPONSOR(S):  Oyster Point Pharma  
MEDICAL DIRECTOR  
 Mina Massaro -Giordano, MD  
ORIGINAL PROTOCOL 
DATE:  February 16, 2023  
VERSION NUMBER:  v.2 
VERSION DATE:  April 27 , 2023  
  
  
Protocol 851655 - The SENSation Study   
OC-01 (varenicline solution) Nasal Spray  Page 3 of 67 
 
 
Confidential and Proprietary Information of  Oyster Point Pharma  
 
1 Study Summary  ................................ ................................ ................................ ..........  8 
1.1 Synopsis  ................................ ................................ ................................ ..................  8 
1.2 Key Roles and Study Governance  ................................ ................................ ..... 10 
1.3 Schema  ................................ ................................ ................................ .......................  11 
2 Introduction and RationalE  ................................ ................................ ....................  13 
2.1 Study Rationale  ................................ ................................ ................................ ... 13 
2.2 Background  ................................ ................................ ................................ ..........  13 
2.2.1  Pharmacokinetics, Pharmacodynamics and Toxicology  ...........................  13 
2.2.2  Assessment for Potential Study Product s Drug -Drug, Drug -Device, 
Device -Device Interactions  ................................ ................................ ...........  16 
2.2.3  Clinical Adverse Event Profile  ................................ ................................ ..... 17 
2.2.4  Dosing Rationale  ................................ ................................ ...........................  17 
2.3 Risk/Benefit Assessment  ................................ ................................ .....................  17 
2.3.1  Known Potential Risks  ................................ ................................ ..................  17 
2.3.2  Known Potential Benefits  ................................ ................................ .............  17 
2.3.3  Assessment of Potential Risks and Benefits  ................................ ................  17 
3 Study Objectives and Endpoints ................................ ................................ .............  19 
4 Study Plan  ................................ ................................ ................................ .................  20 
4.1 Study Design  ................................ ................................ ................................ ........  20 
4.2 Scientific Rationale for Study Design  ................................ ................................  20 
4.3 Justification for Dose  ................................ ................................ ..........................  20 
4.4 End of Study Definition  ................................ ................................ ......................  20 
5 Stud y Population  ................................ ................................ ................................ ...... 21 
5.1 Inclusion Criteria  ................................ ................................ ................................  21 
5.2 Exclusion Criteria  ................................ ................................ ...............................  21 
5.3 Lifestyle Considerations  ................................ ................................ .....................  21 
5.4 Screen Failures  ................................ ................................ ................................ .... 22 
5.5 Strategies for Recruitment and Retention  ................................ ........................  23 
6 Study Intervention  ................................ ................................ ................................ ... 24 
6.1 Study Intervention(s) Administration  ................................ ...............................  24 
6.1.1  Study Intervention Description  ................................ ................................ .... 24 
6.1.2  Dosing and Administration  ................................ ................................ ..........  25 
6.2 Preparation/Handling/Storage/Accountability ................................ .................  25 
6.2.1  Acquisition and accountability  ................................ ................................ .... 25 
6.2.2  Formulation, Appearance, Packaging, and Labeling  ................................  25 
6.2.3  Product Storage and Stability  ................................ ................................ ...... 25 
6.2.4  Preparation  ................................ ................................ ................................ .... 25 
6.3 Measures to Minimize Bias: Randomization and Blinding  .............................  35 
6.4 Study Intervention Compliance  ................................ ................................ .........  35 
6.5 Concomitant Therapy  ................................ ................................ .........................  35 
6.5.1  Rescue Medicine  ................................ ................................ ............................  35  
  
Protocol 851655 - The SENSation Study   
OC-01 (varenicline solution) Nasal Spray  Page 4 of 67 
 
 
Confidential and Proprietary Information of  Oyster Point Pharma  
 
7 Study Intervention Discontinuation and Participant 
Discontinuation/Withdrawal  ................................ ................................ ...................  36 
7.1 Discontinuation of Study Intervention  ................................ ..............................  36 
7.2 Participant Discontinuation/Withdrawal  from the Study  ...............................  36 
7.3 Lost To Follow -Up ................................ ................................ ..............................  37 
8 Study Assessment and Procedures  ................................ ................................ .........  38 
8.1 Efficacy Assessments  ................................ ................................ ...........................  38 
8.2 Safety and Other Assessments  ................................ ................................ ...........  38 
8.3 Adverse Events and Serious Adverse Events  ................................ ...................  39 
8.3.1  Definition of Adverse Events (AE)  ................................ ..............................  39 
8.3.2  Definition of Serious Adverse Events (SAE)  ................................ ...............  39 
8.3.3  Unanticipated Adverse Device Effect (UADE)  ................................ ...........  40 
8.3.4  Classification of an Adverse Event  ................................ ..............................  40 
8.3.5  Time Period and Frequency for Event Assessment and Follow -Up .........  41 
8.3.6  Adverse Event Reporting  ................................ ................................ .............  42 
8.3.7  Serious Adverse Event Reporting  ................................ ................................  42 
8.3.8  Reporting Events to Participants  ................................ ................................ . 43 
8.3.9  Events of Special Interest  ................................ ................................ .............  43 
8.3.10  Reporting of Pregnancy  ................................ ................................ ................  43 
8.4 Unanticipated Problems  ................................ ................................ .....................  43 
8.4.1  Definition of Unanticipated Problems (UP)  ................................ ................  43 
8.4.2  Unanticipated Problem Reporting ................................ ...............................  44 
8.4.3  Reporting Unanticipated Problems To Participants  ................................ . 45 
8.5 Device Reporting  ................................ ................................ ................................ . 45 
9 Statistical Considerations  ................................ ................................ ........................  45 
9.1 Statistical Hypotheses  ................................ ................................ .........................  45 
9.2 Sample Size Determination  ................................ ................................ ................  45 
9.3 Populations for Analyses  ................................ ................................ ....................  45 
9.4 Statistical Analyses  ................................ ................................ ..............................  45 
9.4.1  General Approach  ................................ ................................ .........................  45 
9.4.2  Anal ysis of the Primary Efficacy Endpoint(s)  ................................ ............  45 
9.4.3  Analysis of the Secondary Endpoint(s)  ................................ .......................  46 
9.4.4  Safety Analyses  ................................ ................................ ..............................  46 
9.4.5  Baseline Descriptive Statistics  ................................ ................................ ...... 46 
9.4.6  Planned Interim Analyses ................................ ................................ .............  46 
9.4.7  Sub-Group Analyses  ................................ ................................ .....................  46 
9.4.8  Tabulation of Individual Participant Data  ................................ .................  46 
9.4.9  Exploratory Analyses  ................................ ................................ ....................  46 
10 Supporting Documentation and Operational Considerations  .............................  47 
10.1  Regulatory, Ethical, and Study Oversight Considerations  .............................  47 
10.1.1  Informed Consent Process  ................................ ................................ ............  47 
  
Protocol 851655 - The SENSation Study   
OC-01 (varenicline solution) Nasal Spray  Page 5 of 67 
 
 
Confidential and Proprietary Information of  Oyster Point Pharma  
 
10.1.2  Study Discontinuation and Closure  ................................ .............................  47 
10.1.3  Confidentiality and Privacy  ................................ ................................ .........  48 
10.1.4  Future Use of Stored Specimens and Data  ................................ .................  49 
10.1.5  Safety Oversight  ................................ ................................ ............................  49 
10.1.6  Clinical Monitoring  ................................ ................................ .......................  49 
10.1.7  Quality Assurance and Quality Control  ................................ .....................  49 
10.1.8  Data Handling and Record Keeping  ................................ ...........................  50 
10.1.9  Protocol Deviations  ................................ ................................ .......................  51 
10.1.10  Publication and Data Sharing Policy ................................ ...........................  51 
10.1.11  Conflict of Interest Policy  ................................ ................................ .............  51 
10.2  Additional Considerations  ................................ ................................ ..................  52 
10.3  Protocol Amendment History  ................................ ................................ ............  52 
11 References  ................................ ................................ ................................ .................  52 
12 APPENDIX  ................................ ................................ ................................ ...............  52 
12.1  Schedule of Activities (SoA)  ................................ ................................ ...............  56 
 
  
  
  
Protocol 851655 - The SENSation Study   
OC-01 (varenicline solution) Nasal Spray  Page 6 of 67 
 
 
Confidential and Proprietary Information of  Oyster Point Pharma  
 
 
PRINCIPAL INVESTIGAT OR SIGNATURE  
 
STUDY 
SPONSOR:  Oyster Point Pharma  
STUDY TITLE:  A Single -arm Investigator Initiated Study to Evaluate the Efficacy of OC -01 
(varenicline solution) Nasal Spray on signs and symptoms of Dry Eye 
Disease in subjects with moderate to severe Sjogren’s Syndrome  
STUDY ID  
PROTOCOL 
VERSION  851655  
v1.0 
I have read the referenced protocol. I agree to conduct the study in accordance to this protocol, in 
compliance with the Declaration of Helsinki, Good Clinical Practices (GCP), a nd all applicable 
regulatory requirements and guidelines.  
Principal 
Investigator Name  Giacomina Massaro -
Giordano, MD   Signature   
Affiliation:  Scheie Eye Institute   Date   
     
 
  
Protocol 851655 - The SENSation Study   
OC-01 (varenicline solution) Nasal Spray  Page 7 of 67 
 
 
Confidential and Proprietary Information of  Oyster Point Pharma  
 
Abbreviations  
AE Adverse Event  
FDA  Food and Drug Administration  
HIPAA  Health Insurance Portability and Accountability Act  
IRB Institutional Review Board  
SS Sjogren’s Syndrome  
 
  
  
Protocol 851655 - The SENSation Study   
OC-01 (varenicline solution) Nasal Spray  Page 8 of 67 
 
 
Confidential and Proprietary Information of  Oyster Point Pharma  
 
1 STUDY SUMMARY  
1.1 Synopsis  
Title:  A Single -arm Investigator Initiated Study to Evaluate the Efficacy of OC -
01 (varenicline solution) Nasal Spray on signs and symptoms of Dry Eye 
Disease in subjects with moderate to severe Sjogren’s Syndrome  
Short Title:  The SENSation Study  
Study 
Description :   
Approximately 40 subjects at least 18 years of age with moderate to 
severe Sjogrens syndrome with confir med diagnosis of dry eye disease 
(defined as Schirmers test score 10 mm) will receive an application of 
OC-01 (varenicline solution) 0.03 mg nasal spray twice daily (BID) for 
28 days and will be compared to historical control. The study 
hypothesizes that S S patients treated with OC -01 will demonstrate 
significant improvement in their dry eye symptoms.  
 
Objectives:  To evaluate the safety and effectiveness of OC -01 (varenicline solution) 
nasal spray among subjects with dry eye disease and moderate to severe  
Sjogren’s Syndrome  
 
Primary 
Endpoint:   Mean change in cornea and conjunctival staining from baseline to 
Day 28  
 Mean change in eye dryness score as measured by the Visual 
Analogue Scale (VAS) from baseline to Day 28  
Secondary 
Endpoints:   Mean change in be st corrected visual acuity from baseline to Day 
28 
 Mean change in dry mouth and dry nose scale as measured by 
from baseline through Day 28  
 Incidence and severity of adverse events  
 
Study 
Population:  Sample size: n = 40  
Gender: any  
  
Protocol 851655 - The SENSation Study   
OC-01 (varenicline solution) Nasal Spray  Page 9 of 67 
 
 
Confidential and Proprietary Information of  Oyster Point Pharma  
 
Age: at least age 18 yo 
Demographic group: any  
General health status: see specifics in Inclusion Criteria  
Geographic location: patients at Scheie Eye Institute in Philadelphia, PA  
 
Phase:  Investigator -Initiated Clinical Trial   
Description of 
Sites/Facilities  Scheie Eye Institute  
51 N 39th St.  
Philadelphia, PA 19104  
Enrolling Sites : Scheie Eye Institute will be the only enrolling site.  
Description of 
Study 
Intervention:  Study Drug: OC -01 (varenicline solution) 0.03 mg nasal spray  
Dose/Route/Schedule:  
Intranasal delivery of OC -01 nasal spray twice daily (BID):   
 40 subjects will receive OC -01 (varenicline 0.03 mg) nasal spray 
for 28 days  
 
Schedule of visits:  
 Visit 1 - Screening – Day 1  
 Visit 2 - Day 14 (Virtual visit)  
 Visit 3 - Day 28  
OR possible e arly termination  
Study Duration:  12 months  
Participant 
Duration:  1 month  
  
 
  
Protocol 851655 - The SENSation Study   
OC-01 (varenicline solution) Nasal Spray  Page 10 of 67 
 
 
Confidential and Proprietary Information of  Oyster Point Pharma  
 
1.2 Key Roles and Study Governance  
Sponsor  Medical Director  
 Mina Massaro -Giordano, MD  
Oyster Point Pharma, Inc.  Scheie Eye Institute   
202 Carnegie Center, Suite 106, Princeton, NJ 08540  51 N 39th St, Philadelphia PA 19104  
609-382-9032  215-662-8100  
pshah@oysterpointrx.com  mina@pennmedicine.upenn.edu  
  
  
Protocol 851655 - The SENSation Study   
OC-01 (varenicline solution) Nasal Spray  Page 11 of 67 
 
 
Confidential and Proprietary Information of  Oyster Point Pharma  
 
1.3 Schema  
Study Procedure  Screening/  
Baseline  
(Visit 1)  15 minutes  
Post-
administration   
 
Visit 2   
 
Visit 3  
 Early  
Termination  
 Day -0 Day 0  Day 14 
(Virtual)  Day 28   
Windows for Visits     +/- 2 days  +/- 7 days  
Informed Consent  X     
Demographics  X     
Medical History and 
Concurrent Illnesses  X  X X X 
Ocular History  X  X X X 
Eligibility Criteria  X     
Urine Pregnancy 
Test*  X   X X 
Concomitant 
Medications  X  X X X 
Intranasal Exam via 
history  X     
Eye Dryness Score 
(0-100) as measured 
by Visual Analogue 
Scale (VAS)  X  
X X X 
Nasal Dryness 
Score (0 -100) as 
measured by VAS  X  
X X X 
Dry Mouth Score 
(0-100) as  measured 
by VAS  X  
X X X 
QIDS -SR 
Questionnaire  X  X X X 
Tear Film Imager 
(obtain tear film 
thickness)  X X 
 X  
(15 mins post 
treatment)  X 
  
Protocol 851655 - The SENSation Study   
OC-01 (varenicline solution) Nasal Spray  Page 12 of 67 
 
 
Confidential and Proprietary Information of  Oyster Point Pharma  
 
  Slit Lamp 
Biomicroscopy  X   X X 
Corneal Staining 
using NEI scale & 
Conjunctival 
Staining using Van 
Bijsterveld and 
Utrecht scale  X  
 X X 
Schirmer’s 
Testwithout 
anesthesia  X  
 X X 
Tear sample 
Collection  X   X X 
Ophthalmic 
Examination (w/or 
w/o dilated fundus 
exam)  X  
   
Dispense Study 
Product  X     
Collect Study 
Product     X X 
Adverse Events  X  X X X 
*For women of childbearing potential  
  
Protocol 851655 - The SENSation Study   
OC-01 (varenicline solution) Nasal Spray  Page 13 of 67 
 
 
Confidential and Proprietary Information of  Oyster Point Pharma  
 
2 INTRODUCTION AND RAT IONALE  
2.1 Study Rationale  
Sjögren's syndrome (SS) is a common autoimmune disease affecting about four million 
Americans.  It is a systemic condition that affects the entire body, with the most common 
symptoms being dry eyes, dry mouth, fatigue and pain in the joints.  For Sjogren’s patients, 
inflammation occurs to the tear secreting glands that are responsible for tear production, thus 
resulting in chronic dry eye.  Many current treatments include artificial tears, punctal occlusion, 
and/or ophthalmic therapeutics. We hypothesize the  use of OC -01 in patients who are diagnosed 
with Sjogren’s Syndrome and have confirmed dry eye disease will show beneficial improvement 
in Schirmer’s test score and corneal/conjunctival staining.  
OC-01 (varenicline solution) nasal spray 0.03mg was develope d by Oyster Point Pharma and 
FDA -approved on October 15, 2021 for the treatment of signs and symptoms of dry eye disease. 
OC-01 (varenicline solution) nasal spray is believed to activate the trigeminal parasympathetic 
pathway and stimulate natural tear pro duction to bathe the cornea in a protective layer of tear 
film. This study is testing the hypothesis that OC -01 (varenicline solution) nasal spray 0.03mg 
will improve the signs and symptoms of dry eye disease in subjects with diagnosed Sjogren’s 
syndrome.  
2.2 Background  
The administration of OC -01 0.03 mg and 0.06 mg (varenicline solution) Nasal Spray was safe, 
well tolerated, and efficacious as assessed in the ONSET -1 study of Dry Eye Disease. The 
ONSET -1 study was a multi -center, randomized, masked vehicle -controlled trial of BID OC -01 
nasal spray administered for 28 days.  OC -01 (varenicline) Nasal Spray was safe and well -
tolerated at all concentrations assessed in the ONSET -1 clinical study. Most treatment -emergent 
AEs were mild to moderate in severity, wit h only 1 subject reporting a severe treatment -
emergent AE. The most common AE in all treatment groups was sneezing which was temporally 
related to the administration of the study drug and resolved within a short period of time after 
administration. Sneezin g AEs were characterized as mild to moderate, with no severe AEs 
reported.  
All AEs that were suspected to be related to the study drug with the exception of AEs with each 
of the following terms; nasal dryness, nasal congestion and throat irritation were re ported to be 
recovered/or resolved before study completion. Eleven ocular treatment -emergent AEs were 
reported, 7 of which were reported in the placebo group; all other AEs were classified as non -
ocular. The Investigators considered 3 of the 7 ocular TEAEs  (visual acuity reduced, 
conjunctival hemorrhage, and eyelid oedema) to be possibly related to study drug, all resolved, 
and none was categorized as severe. One treatment emergent  SAE (anemia) was reported and 
was considered to be unrelated to study drug. No treatment -related treatment -emergent SAEs 
were observed. No deaths occurred during the study. Visual acuity, slit -lamp biomicroscopy, 
  
Protocol 851655 - The SENSation Study   
OC-01 (varenicline solution) Nasal Spray  Page 14 of 67 
 
 
Confidential and Proprietary Information of  Oyster Point Pharma  
 
intranasal examination, and pupil diameter did not indicate clinically significant changes from 
baseline.  
The administr ation of OC -01 (varenicline solution) nasal spray, 0.03 mg and 0.06 mg was safe, 
well tolerated, and efficacious as assessed in the ONSET -2 study of Dry Eye Disease. The 
ONSET -2 study was a multi -center, randomized, masked vehicle -controlled trial of BID O C-01 
nasal spray administered for 28 days.  In the ONSET -2 study, the most commonly reported 
ocular treatment -emergent AE by PT was conjunctival hyperemia (4.6% and 4.5% of subjects in 
the 0.006 mg/mL and 0.06 mg OC -01 groups, respectively, and 2.8% of sub jects in the placebo 
group). The incidences of other commonly reported ocular treatment -emergent AEs by PT were 
similar across the 0.03 mg OC -01, the 0.06 mg OC 01, and the placebo groups: visual acuity 
reduced (3.5%, 3.7%, and 4.4% of subjects, respective ly), blepharitis (1.2%, 0.4%, and 0.4% of 
subjects, respectively), and eye irritation (0.4%, 0.4% and 1.2% of subjects, respectively).  
The incidences of the most commonly reported non -ocular treatment -emergent AEs were higher 
in the 0.03 mg and the 0.06 m g OC 01 groups compared with the placebo group: sneezing 
(95.0% and 96.7% vs. 29.1% of subjects, respectively), cough (18.8% and 22.0% vs. 2.0% of 
subjects, respectively), and throat irritation (13.5% and 18.0% vs. 2.0% of subjects, 
respectively). The most  common treatment -emergent AE in both the OC -01 and placebo groups, 
sneezing, was likely caused by stimulation of the trigeminal nerve (and to some extent, due to the 
mechanical administration of the nasal spray, as demonstrated by the sneezing in the plac ebo 
group). With the exception of one instance of cough considered not related to study drug by the 
Investigator in the 0.06 mg OC -01 group, all instances of sneezing, cough, and throat irritation 
were considered related to study drug, and all instances of  sneezing, cough, and throat irritation 
were mild and non -serious.  
Most treatment -emergent AEs were mild in severity. The incidence of subjects with severe 
treatment -emergent AEs was low across all treatment groups: 2 (0.8%), 3 (1.2%), and 2 (0.8%) 
subject s in the 0.03 mg OC -01, 0.06 mg OC 01, and placebo groups, respectively; none were 
classified as ocular treatment -emergent AEs.  
No deaths were reported during the ONSET -2 study. Overall, 10 subjects (1.3%) overall reported 
serious treatment -emergent AEs: 2 (0.8%), 5 (2.0%), and 3 (1.2%) subjects in the 0.03 mg OC -
01, 0.06 mg OC -01, and placebo groups, respectively. All serious treatment -emergent AEs were 
either moderate or severe in intensity; none were considered related to study drug, and none were 
fatal.  
Sneezing data collected from subject diaries showed that almost all sneezing instances were mild 
among the treatment groups (no intervention was needed). In the OC -01 groups, approximately 
50% of administrations caused any sneezing; approximately 80% of  administrations caused 0 to 
2 sneezes, approximately 20% of administrations caused 3 to 5 sneezes, and ≤5% of 
administrations caused ≥6 sneezes. Among subjects who sneezed after administration, the 
majority of sneezing was experienced within the first min ute and stopped within the first 5 
minutes in the OC 01 groups.  
  
Protocol 851655 - The SENSation Study   
OC-01 (varenicline solution) Nasal Spray  Page 15 of 67 
 
 
Confidential and Proprietary Information of  Oyster Point Pharma  
 
Visual acuity, slit lamp biomicroscopy, intranasal examination, and pupil diameter did not 
indicate any clinically relevant changes from baseline.  
These data from the ONSET -1 and ONSET -2 stud y suggest that 28 days of BID delivery of OC -
01 (varenicline solution) Nasal Spray is safe and efficacious in subjects with DED.   
The MYSTIC study was designed to provide efficacy and safety data on chronic dosing of OC -
01 (varenicline solution) nasal spra y for up to 84 days of BID treatment. OC -01 nasal spray was 
shown to be safe and well tolerated at both concentrations assessed in this clinical study. The 
only ocular treatment -emergent AE  reported in more than 1 subject was visual acuity reduced, 
with si milar frequencies in the placebo (7.3%) and OC -01 groups (0.03 mg [9.8%] and 0.06 mg 
[7.3%]).  
Most treatment -emergent AEs  were mild in severity; no severe treatment -emergent AEs  were 
reported. All treatment -emergent AEs  assessed as related to the study dru g by the Investigator 
were reported to be recovered or resolved before study completion with the exception of two 
cases each of visual acuity reduced and sneezing in subjects treated with OC -01 and eyelid 
edema in 1 subject treated with placebo.  No SAEs or  deaths were reported.  
2.2.1 Pharmacokinetics , Pharmacodynamics and Toxicology  
TYRVAYA nasal spray contains varenicline which is a partial nicotinic acetylcholine receptor  
agonist of α4β2, α4α6β2, α3β4, and α3α5β4 receptors and a full α7 receptor agonist.  
Varenicline, as the tartrate salt, is a powder which is a white to off -white to slightly yellow solid  
whose chemical name is 7,8,9,10 -tetrahydro -6,10-methano -6H-pyrazino[2,3 -h][3]benzazepine,  
(2R,3R) -2,3-dihydroxybutanedioate (1:1). It is highly soluble in  water. Varenicline tartrate has a  
molecular weight of 361.35 Daltons and a molecular formula of C 13H13N3 ⋅ C4H6O6.  
 
TYRVAYA (varenicline solution) nasal spray is formulated for intranasal use as a clear  
0.6 mg/mL strength solution, at pH 6.4. After priming , each actuation delivers a 0.05 mL spray 
containing 0.03 mg varenicline free base, equivalent to  0.05 mg of varenicline tartrate. The 
formulation also contains the following inactive ingredients:  
sodium phosphate dibasic heptahydrate, monobasic sod ium phosphate anhydrous, sodium  
chloride, sodium hydroxide and/or hydrochloric acid (to adjust pH) and water for injection.  
 
The efficacy of TYRVAYA in dry eye disease is believed to be the result of varenicline's activity  
at heteromeric sub -type(s) of the  nicotinic acetylcholine (nACh) receptor where its binding  
produces agonist activity and activates the trigeminal parasympathetic pathway resulting in  
increased production of basal tear film as a treatment for dry eye disease. Varenicline binds with  
high a ffinity and selectivity at human α4β2, α4α6β2, α3β4, α3α5β4 and α7 neuronal nicotinic  
acetylcholine receptors. The exact mechanism of action is unknown at this time.  
 
Following administration of 0.12 mg (0.06 mg per 50 -μL spray in each nostril), a strength  of 
varenicline that is higher than the labeled concentration, varenicline can be detected in plasma by  
  
Protocol 851655 - The SENSation Study   
OC-01 (varenicline solution) Nasal Spray  Page 16 of 67 
 
 
Confidential and Proprietary Information of  Oyster Point Pharma  
 
5 minutes, generally achieves peak concentration within 2 hours, with a mean C max of 0.34  
ng/mL, and has an AUC 0-inf of 7.46 h*ng/mL. The systemic exposure (AUC 0-inf) following this  
intranasal dose was approximately 7.5% of the exposure observed following a 1 mg oral dose of  
varenicline.  
 
The mean ± SD elimination half -life of varenicline after intranasal administration is  
approximately 19 ± 10 hours. Varenicline undergoes minimal metabolism with 92% excreted as  
unchanged drug in the urine.  
 
NONCLINICAL TOXICOLOGY  
Carcinogenesis  
Lifetime carcinogenicity studies were performed in CD -1 mice and Sprague -Dawley rats. There  
was no evidence of a carcin ogenic effect in mice administered varenicline by oral gavage for 2  
years at doses up to 20 mg/kg/day (810 times the maximum recommended human dose  
[MRHD], on a mg/m 2 basis). Rats were administered varenicline (1, 5, and 15 mg/kg/day) by  
oral gavage for 2 years. In male rats (n = 65 per sex per dose group), incidences of hibernoma 
(tumor of the brown fat) were increased at the mid dose (1 tumor, 5 mg/kg/day, 405 times the  
MRHD on a mg/m 2 basis) and maximum dose (2 tumors, 15 mg/kg/day, 1216 times the MRHD  
on a mg/m 2 basis). The clinical relevance of this finding to humans has not been established.  
There was no evidence of carcinogenicity in female rats.  
Mutagenesis  
Varenicline was not genotoxic, with or without metabolic activation, in the following assays:  
Ames bacterial mutation assay; mammalian CHO/HGPRT assay; and tests for cytogenetic  
aberrations in vivo in rat bone marrow and in vitro in human lymphocytes.  
Impairment of Fertility  
There was no evidence of impairment of fertility in either male or female Sprague -Dawley rats  
administered varenicline succinate up to 15 mg/kg/day (1216 times the MRHD on a mg/m 2 
basis). Maternal toxicity, characterized by a decrease in body weight gain, was observed at 15  
mg/kg/day. A decrease in fertility was noted in the off spring of pregnant rats administered  
varenicline succinate at an oral dose of 15 mg/kg/day. The decrease in fertility in the offspring of  
treated female rats was not evident at an oral dose of 3 mg/kg/day (243 times the MRHD, on a  
mg/m 2 basis).  
 
2.2.2 Assessment  for Potential Study Products Drug -Drug, Drug -Device, Device -Device 
Interactions  
There are no known drug interactions for TYRVAYA varenicline solution) nasal spray.   
 
  
Protocol 851655 - The SENSation Study   
OC-01 (varenicline solution) Nasal Spray  Page 17 of 67 
 
 
Confidential and Proprietary Information of  Oyster Point Pharma  
 
2.2.3 Clinical Adverse Event Profile  
Because clini cal trials are conducted under widely varying conditions, adverse reaction rates  
observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials  
of another drug and may not reflect the rates observed in practice.  
In three clinical studies of dry eye disease conducted with varenicline solution nasal spray, 349  
patients received at least 1 dose of TYRVAYA. The majority of patients had 31 days of  
treatment exposure, with a maximum exposure of 105 days.  
The most common adve rse reactions reported in 82% of TYRVAYA treated patients was  
sneezing. Other common adverse reactions that were reported in >5% of patients include cough  
(16%), throat irritation (13%), and instillation -site (nose) irritation (8%).  
2.2.4 Dosing R ationale  
These data from the ONSET -1 and ONSET -2 study suggest that 28 days of BID delivery of OC -
01 (varenicline solution) Nasal Spray is safe and efficacious in subjects with DED.   
2.3 Risk/Benefit Assessment  
2.3.1 Known Potential Risks  
In 3 clinical stud ies conducted with OC -01 (varenicline) n asal spray, the most common side 
effects reported in ≥2%  of treated subjects at a frequency greater than placebo :  
 sneezing  (84%)  
 coughing  (19%)  
 throat irritation (16%)  
 instillation site irritation (13%)  
 conjunctival hyperemia (eye redness) (3%)  
 headache (2.4%)  
 rhinorrhea  (runny nose) (2.4%)  
 reduced visual acuity (2.1%)  
2.3.2 Known Potential Benefits  
You may or may not directly benefit medically from taking part in this study. You may gain 
information about your health from the different tests (e.g., eye exams, etc.) that are done. It is 
possible that if you have dry eye disease from Sjogren’s Syndrome, your signs and/or symptoms 
of dry eye disease may get better, stay the same, or get worse. Information from this study may 
help doctors learn things about OC -01 (varenicline solution) nasal spray that could help others 
with dry eye disease due to Sjogren’s.  
  
Protocol 851655 - The SENSation Study   
OC-01 (varenicline solution) Nasal Spray  Page 18 of 67 
 
 
Confidential and Proprietary Information of  Oyster Point Pharma  
 
2.3.3 Assessment of Potential Risks and Benefits  
 
Based on clinical trial data, m ost treatment -emergent AEs  were mild in severit y; no severe 
treatment -emergent AEs  were reported.  
Benefits include possible improvement in dry eye symptoms.  
  
Protocol 851655 - The SENSation Study   
OC-01 (varenicline solution) Nasal Spray  Page 19 of 67 
 
 
Confidential and Proprietary Information of  Oyster Point Pharma  
 
3 STUDY OBJECTIVES AND ENDPOINTS  
 
OBJECTIVES  ENDPOINTS  JUSTIFICATION FOR 
ENDPOINTS  
Primary    
Evaluate the safety and 
effectiveness of OC -01 
(varenicline solution) nasal spray 
among subjects with dry eye 
disease and moderate to severe 
Sjogren’s Syndrome  Mean change in cornea and 
conjunctival staining from 
baseline to Day 28  
Mean change in eye dryness score 
as measured by the Visual 
Analogue Scale (VAS) from 
baseline to Day 28   
Secondary    
 Mean change in best corrected 
visual acuity from baseline to 
Day 28  
Mean change in dry mouth and 
dry nose scale as measured by 
from baseline through Day 28  
Incidence and severity of 
adverse events  
 To assess secondary 
endpoints such as visual 
acuity, safety, dry 
mouth/nose.  
  
Protocol 851655 - The SENSation Study   
OC-01 (varenicline solution) Nasal Spray  Page 20 of 67 
 
 
Confidential and Proprietary Information of  Oyster Point Pharma  
 
4 STUDY PLAN  
4.1 Study Design  
This is a single -center, single -arm study to assess the efficacy of OC -01 (varenicline solution) 
nasal spray in  signs and symptoms of dry eye disease for subjects with diagnosed Sjogren’s 
syndrome.  
Approximately 40 subjects at least 18 years of age with moderate to severe Sjogren’s syndrome 
with confirmed diagnosis of dry eye disease (defined as Schirmer’s test sco re ≤10 mm and 
meeting all other study eligibility criteria. 40 subjects will receive an application of OC -01 
(varenicline solution) 0.03 mg nasal spray twice daily (BID) and will be compared to age -
matched historical control.    
Subjects who terminate earl y during the application period will be asked to complete safety 
assessments (if subjects agree) prior to study exit. Subjects who are terminated early from the 
study will not be replaced.  
4.2 Scientific Rationale for Study Design  
This study is a single center, single -arm, investigator -initiated study to investigate the efficacy of 
OC-01 on signs and symptoms of dry eye disease with moderate to severe Sjogren’s syndrome.   
4.3 Justification for Dose  
The dosing and schedule is as was use d in previous clinical trials of this drug .  
4.4 End of Study Definition  
A participant is considered to have completed the study if he or she has completed all phases of 
the study including the last visit .
  
Protocol 851655 - The SENSation Study   
OC-01 (varenicline solution) Nasal Spray  Page 21 of 67 
 
 
Confidential and Proprietary Information of  Oyster Point Pharma  
 
Study Population  
4.5 Inclusion Criteria  
Subjects must:  
 Provide signed written consent prior to study -related procedures  
 Be at least 18 years of age at the screening visit  
 Have diagnosed moderate to severe Sjogrens Syndrome via blood work or biopsy 
Category 2 staining score for Conjunctiva based on the Van Bjis terveld and Utrect scale 
and 3 staining score for cornea based on the NEI scale  
 Have continuous use of all topical ocular medication for > 3 months and willingness to 
continue until completion of the study  
 Be literate and able to complete questionnaires in dependently  
 Be able and willing to use the study drug and participate in all study assessments and 
visits  
 Have sufficient hand strength, in the opinion of the Investigator, to be able to 
independently administer the study drug  
 Have provided verbal and writ ten informed consent  
 If a female is of childbearing potential, they must: use an acceptable means of birth 
control (acceptable methods of contraception include: hormonal oral, implantable, 
injectable, or transdermal contraceptives, mechanical spermicide in  conjunction with a 
barrier such as a diaphragm or condom, IUD, or surgical sterilization of partner), and 
have a negative urine pregnancy test on Day 1  
4.6 Exclusion Criteria  
Subjects must not:  
 Have undergone previous ocular surgery (e.g., intraocular, oculop lastic, corneal or 
refractive surgical procedure)  in the past 1 year  
 Have had thermal pulsation or IPL in prior 3 months  
 Have used topical ophthalmic corticosteroid therapy in prior 4 weeks  
 Have had cataract surgery in the last 6 months  
 Have clinically significant ocular trauma.  
 Have active ocular Herpes simplex or Herpes Zoster infection  
 Have ocular inflammation (uveitis, iritis, scleritis, episcleritis, keratitis, conjunctivitis) at 
the discretion of the investigator.  
 Have ocular infection (e.g., viral , bacterial, mycobacterial, protozoan or fungal infection 
or the cornea, conjunctiva, lacrimal gland, lacrimal sac or eyelids including 
hordeolum/stye).  
 Have retinal pathology that can limit visual potential and refractive outcomes in the 
opinion of the in vestigator  
  
Protocol 851655 - The SENSation Study   
OC-01 (varenicline solution) Nasal Spray  Page 22 of 67 
 
 
Confidential and Proprietary Information of  Oyster Point Pharma  
 
 Have severe (Grade 3 or 4) inflammation of the eyelid (e.g., blepharochalasis, 
staphylococcal blepharitis or seborrheic blepharitis)  
 Have eyelid abnormalities that significantly affect the lid function (e.g., entropion, 
ectropion, tumor, edema, blepharospasm, lagophthalmos, severe trichiasis, severe ptosis).  
 Have ocular surface abnormality that may compromise the corneal integrity (e.g., prior 
chemical burn, recurrent corneal erosion, corneal epithelial defect, Grade 3 corneal 
fluorescein staining, map dot fingerprint dystrophy, or the effect of any other ophthalmic 
medication that might in the opinion of the investigator compromise the ocular surface 
integrity).  
 Have a systemic condition or disease not stabilized or judged by the Investiga tor to be 
incompatible with participation in the study or with the lengthier assessments required by 
the study (e.g., current systemic infection, uncontrolled autoimmune disease, 
uncontrolled immunodeficiency disease, history of myocardial infarction or he art disease, 
etc.) 
 Have chronic or recurrent epistaxis, coagulation disorders or other conditions that, in the 
opinion of the Investigator, may lead to clinically significant risk of increased bleeding.  
 Have had nasal or sinus surgery (including history of  application of nasal cautery) or 
significant trauma to these areas  
 Be currently treated with nasal continuous positive airway pressure  
 Have any untreated nasal infection at Visit 1  
 Have a vascularized polyp, severely deviated septum, chronic recurrent nos ebleeds, or 
severe nasal obstruction as confirmed by intranasal examination performed at Visit 1.  
 Have a known hypersensitivity to any of the procedural agents or study drug components  
 Be currently enrolled in an investigational drug or device study or hav e used an 
investigational drug or device within 30 days prior to Visit 1 and during the treatment 
period.  
 Be a female who is pregnant, nursing, or planning a pregnancy at Visit 1. Be a woman of 
childbearing potential who is not using an acceptable means of  birth control; acceptable 
methods of contraception include: hormonal oral, implantable, injectable, or transdermal 
contraceptives; mechanical spermicide in conjunction with a barrier such as a diaphragm 
or condom; IUD; or surgical sterilization of partner . The risks of OC -01 among pregnant 
patients are not known.  
4.7 Lifestyle Considerations  
During this study, patients will be asked to refrain from activities as listed above in the exclusion 
criteria. If they are unable to do so, then they will be excluded fro m the study.  
4.8 Screen Failures  
Screen failures are defined as participants who consent to participate in the clinical trial but are 
not eligible to entered in the study. A minimal set of screen failure information is required to 
  
Protocol 851655 - The SENSation Study   
OC-01 (varenicline solution) Nasal Spray  Page 23 of 67 
 
 
Confidential and Proprietary Information of  Oyster Point Pharma  
 
ensure transparent reporting  of screen failure participants, to meet the Consolidated Standards of 
Reporting Trials (CONSORT) publishing requirements and to respond to queries from regulatory 
authorities. Minimal information includes demography, screen failure details, eligibility cr iteria, 
and any serious adverse event (SAE).  
4.9 Strategies for Recruitment and Retention  
Subjects will be recruited in the outpatient clinic setting from dry eye patients who are seen at 
Scheie Eye Institute. ***  
  
Protocol 851655 - The SENSation Study   
OC-01 (varenicline solution) Nasal Spray  Page 24 of 67 
 
 
Confidential and Proprietary Information of  Oyster Point Pharma  
 
5 STUDY INTERVENTION  
5.1 Study Intervention(s) Administration  
5.1.1 Study Intervention Description  
Package Insert Patient information:  
 

  
Protocol 851655 - The SENSation Study   
OC-01 (varenicline solution) Nasal Spray  Page 25 of 67 
 
 
Confidential and Proprietary Information of  Oyster Point Pharma  
 
5.1.2 Dosing and Administration  
Spray TYRVAYA once in each nostril twice daily (approximately 12 hours apart). If a dose is  
missed, resume regular dosing at the next scheduled dose time.  
 
Priming Instructions  
Priming: Prime TYRVAYA before initial use by pumping seven (7) actuations into the air away  
from the face. When TYRVAYA has not been used for more than 5 days, re -prime with 1 spray  
into the air. Do not shake.  
 
DOSAGE FORMS  AND STRENGTHS  
Nasal spray delivering 0.03 mg of varenicline in each spray (0.05 mL).  
5.2 Preparation/Handling/Storage/Accountability  
5.2.1 Acquisition and accountability  
Oyster Point Pharma will provide sufficient drug for the study in its commercially available 
form.  
5.2.2 Formulation, Appearance, Packaging, and Labeling  
Investigational drug will be provided in multi -use intranasal applicator.  
The investigational drug must be stored in accordance with the pharmacy manual for this study, 
which contains detailed information regarding the storage and administration  
The study drug will be delivered as a 50 microliter (µL) intranasal spray in each nostril BID:  
 OC-01 (varenicline solution) nasal spray, 0.03 mg  
General Appearance  
 OC-01 (varenicline solution) will be f ormulated at the desired concentration in 
sodium phosphate buffers and sodium chloride as an aqueous solution and presented 
in a multi -use preservative -free nasal pump.  
 The product is preservative -free and intended for intranasal use only. The product 
shou ld not be used if cloudy or if particulate matter is present.  
 OC-01 (varenicline solution) must be administered without dilution.  
5.2.3 Product Storage and Stability  
 Store TYRVAYA nasal spray at 20°C to 25°C (68°F to 77°F). Do not freeze.  
 Discard TYRVAYA nasal spray bottle 30 days after opening bottle.  
  
Protocol 851655 - The SENSation Study   
OC-01 (varenicline solution) Nasal Spray  Page 26 of 67 
 
 
Confidential and Proprietary Information of  Oyster Point Pharma  
 
5.2.4 Preparation  
Preparation  
1. Tear off removable portion of vial label and place on appropriate source 
document.  Ensure that subject ID is noted on vial label.  
2. Remove plastic safety clip and cap from the nasal pu mp (see Figure 1).  
 
3. Discard the plastic safety clip and remove and set the cap aside (Figure 2).  

  
Protocol 851655 - The SENSation Study   
OC-01 (varenicline solution) Nasal Spray  Page 27 of 67 
 
 
Confidential and Proprietary Information of  Oyster Point Pharma  
 
 
4. Hold the nasal pump upright and away from your face.  Place one finger on each 
side of the base of the nasal applicator and your thumb underneath the bottl e (see 
Figure 3).  

  
Protocol 851655 - The SENSation Study   
OC-01 (varenicline solution) Nasal Spray  Page 28 of 67 
 
 
Confidential and Proprietary Information of  Oyster Point Pharma  
 
 
5.  Completely press (pump) the nasal pump 7 times by squeezing your thumbs and 
fingers together. This will prime the pump for use (see Figure 4).  
 
6. OC-01 is now ready to administer.  

  
Protocol 851655 - The SENSation Study   
OC-01 (varenicline solution) Nasal Spray  Page 29 of 67 
 
 
Confidential and Proprietary Information of  Oyster Point Pharma  
 
Administration  
7. Instruct the subject to blow their nose to clear their nostrils (see Figure 5).  
 
8. Have the subject hold the bottle upright (see Figure 6).  

  
Protocol 851655 - The SENSation Study   
OC-01 (varenicline solution) Nasal Spray  Page 30 of 67 
 
 
Confidential and Proprietary Information of  Oyster Point Pharma  
 
 
  

  
Protocol 851655 - The SENSation Study   
OC-01 (varenicline solution) Nasal Spray  Page 31 of 67 
 
 
Confidential and Proprietary Information of  Oyster Point Pharma  
 
 
9. Have the subject tilt their head back slightly (see Figure 7).  
 
NOTE: Nasal applicator MUST be held in an upright position to deliver the correct 
dose.   Do not instruct the subject to lie down or tilt their head too far back while 
OC-01 is being administered.  
 
10. Instruct the subject to insert the intranasal applicator into the left or right nostril.  
Have the subject keep the intranasal applicator in the opposite  hand from the 
nostril which they are administering spray info.  Have them place the tip into the 
nasal cavity far enough to avoid nasal hairs.  Have them aim the tip of the nasal 
spray pump to the top of their ear on the same  side as the nostril (see Figure 8).  

  
Protocol 851655 - The SENSation Study   
OC-01 (varenicline solution) Nasal Spray  Page 32 of 67 
 
 
Confidential and Proprietary Information of  Oyster Point Pharma  
 
 
  

  
Protocol 851655 - The SENSation Study   
OC-01 (varenicline solution) Nasal Spray  Page 33 of 67 
 
 
Confidential and Proprietary Information of  Oyster Point Pharma  
 
11. Instruct the subject to place their tongue to the roof of their mouth (closing the 
soft palate to minimize drug into the throat) and have them breathe in (inhale) 
gently while they pump the intranasal applicator one  time, aiming outward toward 
the top of the ear on the same side (see Figure 9).   
 
 
12. Have the subject gently breathe in through the nose and out through the mouth 
several times.  
13. Have the subject repeat this administration with the other nostril.  
14. Instruct the subject to wipe the intranasal applicator with a clean tissue (see 
Figure 10).  
15.  

  
Protocol 851655 - The SENSation Study   
OC-01 (varenicline solution) Nasal Spray  Page 34 of 67 
 
 
Confidential and Proprietary Information of  Oyster Point Pharma  
 
 
 
16. Replace plastic safety cap (see Figure 11).  
 

  
Protocol 851655 - The SENSation Study   
OC-01 (varenicline solution) Nasal Spray  Page 35 of 67 
 
 
Confidential and Proprietary Information of  Oyster Point Pharma  
 
 
5.3 Measures to Minimize Bias: Randomization and Blinding  
This is a single -arm study which does not involve randomization or b linding.  
5.4 Study Intervention Compliance  
Adherence to protocol will be documented in the electronic medical record and use of the drug 
will be self -reported by patients.  
5.5 Concomitant Therapy  
At the discretion of their physician, patients may continue to rec eive all medications and 
standard treatments administered for other conditions.  
5.5.1 Rescue Medicine  
Not applicable.  
  
Protocol 851655 - The SENSation Study   
OC-01 (varenicline solution) Nasal Spray  Page 36 of 67 
 
 
Confidential and Proprietary Information of  Oyster Point Pharma  
 
6 STUDY INTERVENTION D ISCONTINUATION AND P ARTICIPANT 
DISCONTINUATION/WITH DRAWAL  
6.1 Discontinuation of Study Intervention  
Discontinuation from use of  the study dru g does not mean discontinuation from the study, and 
remaining study procedures should be completed as in dicated by the study protocol. If a 
clinically significant finding is identified (including, but not limited to changes from baseline) 
after enrollment, the investigator or qualified designee will determine if any change in participant 
management is needed. Any new clinically relevant finding will be reported as an adverse event 
(AE).  
The data to be collected at the time of study interven tion discontinuation  (i.e. Early Termination 
visit)  will include the following:  
 Record of any changes in medical/surgical history  
 Collection of current ocular and systemic medications  
 Eye/Nasal/Mouth Dryness Score as measured by Visual Analogue Scale  
 QIDS -SR Questionnaire  
 Tear Film Imager (5 mins post treatment administration)  
 Subjective Refraction  
 Best-corrected visual acuity  
 Slit lamp biomicroscopy  
 Corneal and Conjunctival Staining  
 Schirmer’s Test with out Anesthesia  
 Collect Schirmer’s test strips  
 Adver se Events (AEs): Documentation of monitoring of AEs  
 Collect Study Product  
6.2 Participant Discontinuation/Withdrawal from the Study  
Participants are free to withdraw from participation in the study at any time upon request.  
An investigator may discontinue or w ithdraw a participant from the study for the following 
reasons:  
 Pregnancy  
 Significant drug non-compliance  
 If any clinical adverse event (AE), laboratory abnormality, or other medical condition or 
situation occurs such that continued participation in the st udy would not be in the best 
interest of the participant  
 Disease progression which requires discontinuation of the drug 
  
Protocol 851655 - The SENSation Study   
OC-01 (varenicline solution) Nasal Spray  Page 37 of 67 
 
 
Confidential and Proprietary Information of  Oyster Point Pharma  
 
 If the participant meets an exclusion criterion (either newly developed or not previously 
recognized) that precludes further study parti cipation  
 Participant unable to receive drug for 1 day  
 
6.3 Lost To Follow -Up 
 
The following actions  must be taken if a participant fails to return to the clinic for a required 
study visit:  
 The site will attempt to contact the participant and reschedule the missed visit within 1 
week  and counsel the participant on the importance of maintaining the assign ed visit 
schedule and ascertain if the participant wishes to and/or should continue in the study.  
 Before a participant is deemed lost to follow -up, the investigator or designee will make 
every effort to regain contact with the participant (where possible, 3 telephone calls and, 
if necessary, a certified letter to the participant’s last known mailing address or local 
equivalent methods). These contact attempts should be documented in the participant’s 
medical record or study file.  
 Should the participant con tinue to be unreachable, he or she will be considered to have 
withdrawn from the study with a primary reason of lost to follow -up. 
  
Protocol 851655 - The SENSation Study   
OC-01 (varenicline solution) Nasal Spray  Page 38 of 67 
 
 
Confidential and Proprietary Information of  Oyster Point Pharma  
 
7 STUDY  ASSESSMENT AND PROCE DURES  
7.1 Efficacy Assessments  
 Eye Dryness Score as measured by Visual Analogue Scale (VAS): Symptoms of ocular 
comfort and dryness will be graded for each eye on a scale of 0 -100, where 0=no 
discomfort and 100=maximum discomfort. An average rating will be provided for the 
morning, afternoon and evening (See Appendix I)  
 Nasal Dryness Score as measured by V AS: Symptoms of nasal dryness will be graded for 
each nostril on a scale of 0 -100, where 0=no discomfort and 100=maximum discomfort. 
An average rating will be provided for the morning, afternoon and evening (see Appendix 
I) 
 Mouth Dryness Score as measured by VAS: Symptoms of mouth dryness will be graded 
on a scale of 0 -100, where 0=no discomfort and 100=maximum discomfort. An average 
rating will be provided for the morning, afternoon and evening (see Appendix I)  
 The Quick Inventory of Depressive Symptomatol ogy Self report (QIDS -SR): It is a self -
report tool of 16 questions designed to screen for depression and measure changes in 
severity of symptoms. ( See Appendix II)  
 The Tear Film Imager quantifies the dynamic properties of the tear film inner layers 
(muco -aqueous layer and lipid layer) using a single non -contact measurement. The Tear 
Film Imager’s measurement features the natural behavior of the tears while allowing the 
patient to blink naturally (See Appendix III)  
 Eye Examination  
 Best-corrected visual acui ty - routine visual acuity (not standardized or by certified 
technician)  
 Slit lamp biomicroscopy: assessment of eyelids, conjunctiva, cornea, lens, iris, and 
anterior chamber. Observations will be graded as Normal  or Abnormal .  Abnormal 
findings, which are  clinically significant, will be described.  
 Corneal Staining/Conjunctival Staining: The appearance of tissue disruption or other 
pathophysiological changes in the anterior eye.  These changes are typically seen with the 
use of fluorescein dye. The NEI scal e is the method that will be used to measure corneal 
staining using fluorescein strips.  It divides the corneal and conjunctival surfaces to help 
measure fluorescein uptake. The Van Bijsterveld and Utrecht scale is the method that will 
be used to measure c onjunctival staining while using lissamine green dye (See Appendix 
IV) 
 Schirmer’s Test with out anesthesia: A filter paper inside the lower lid of the eye to 
determine whether the eye produces enough tears.  The paper is removed after 5 -minutes 
and the mois ture is measured  
 Collection of Schirmer’s test strips: Place Schirmer’s strips into tubes for further study.  
Place tubes into a -20 to -80 degree freezer until shipped onto dry ice to lab.  (See 
Appendix V)  
  
Protocol 851655 - The SENSation Study   
OC-01 (varenicline solution) Nasal Spray  Page 39 of 67 
 
 
Confidential and Proprietary Information of  Oyster Point Pharma  
 
 Dilated Fundus Exam: assessment of posterior ret ina, lens, and vitreous.  
7.2 Safety and Other Assessments  
 Collection of current ocular and systemic medications  
 Eye/Nasal/Mouth Dryness Score as measured by Visual Analogue Scale  
 QIDS -SR Questionnaire  
 Tear Film Imager (5 mins post treatment administration)  
 Subjective Refraction  
 Best-corrected visual acuity  
 Slit lamp biomicroscopy  
 Corneal and Conjunctival Staining  
 Schirmer’s Test with out Anesthesia  
 Collect Schirmer’s test strips  
 Urine Pregnancy Test  
 Adverse Events (AEs): Documentation of monitoring of AEs  
7.3 Adverse Events and Serious Adverse Events  
7.3.1 Definition of Adverse Events (AE)  
An adverse event (AE) is any untoward medical occurrence associated with the use of an 
intervention  in humans, whether or not considered intervention related. Intercurrent illnesses  or 
injuries should be regarded as adverse events.  
A pre -existing condition should be recorded as an adverse event if the frequency, intensity or the 
character of the condition changes.  
7.3.2 Definition of Serious Adverse Events (SAE)  
Serious Adverse Events (SAE)  
Adverse events are classif ied as serious or non -serious. A serious adverse event is any AE that, 
in the view of either the i nvestigator or the sponsor, is:  
 fatal 
 life-threatening  
 requires or prolongs hospital stay  
 results in persistent or significant  disability or incapacity  
 a congenital anomaly or birth defect  
  
Protocol 851655 - The SENSation Study   
OC-01 (varenicline solution) Nasal Spray  Page 40 of 67 
 
 
Confidential and Proprietary Information of  Oyster Point Pharma  
 
 an important medical event  when the event does not fit the other outcomes, but the event 
may jeopardize the patient and may require medical or surgical intervention (treatment) 
to prevent one o f the other outcomes.  
 required intervention to prevent permanent impairment or damage ( for devices  only) 
Important medical events are those that may not be immediately life threatening but  are clearly 
of major clinical significance. They may jeopardize the subject and  may require intervention to 
prevent one of the other serious ou tcomes noted above. For example, drug overdose or abuse, a 
seizure that did not result in in -patient hospitalization, or intensive treatment of bronchospasm in 
an emergency department would typically be considered serious.  
7.3.3 Unanticipated Adverse Device Effect (UADE)  
Unanticipated Adverse Device Effect (UADE)  
A UADE is any serious adverse effect on health or safety, or any life -threatening problem or 
death caused by, or associated with, a device, if that effect, problem, or death was not previously 
identified in nature, severity, or degree of incidence in the investigational plan or application, or 
any other unanticipated serious problem associated with a de vice that relates to the rights, safety, 
or welfare of subjects.  
Classification of an Adverse Event  
7.3.3.1  Severity of Event  
For adverse events (AEs) not included in the protocol defined grading system, the following 
guidelines wil l be used to describe severity.  
 Mild – Events require minimal or no treatment and do not interfere with the participant’s 
daily activities.  
 Moderate – Events result in a low level of inconvenience or concern with the therapeutic 
measures. Moderate events may cause some interference with  functioning.  
 Severe – Events interrupt a participant’s usual daily activity and may require systemic 
drug therapy or other treatment. Severe events are usually potentially  life-threatening or 
incapacitating.  Of note, the term “severe” does not necessarily  equate to “serious”.  
7.3.3.2  Relationship to Study Intervention  
All adverse events (AEs) must have their relationship to the drug  assessed by the clinician who 
examines and evaluates the participant based on temporal relationship and his/her clinical 
judgment. Th e degree of certainty about causality will be graded using the categories below. In a 
clinical trial, the study product must always be considered . 
 Related – The AE is known to occur with the drug, there is a reasonable possibility that 
the drug caused the AE, or there is a temporal relationship between the drug and event. 
  
Protocol 851655 - The SENSation Study   
OC-01 (varenicline solution) Nasal Spray  Page 41 of 67 
 
 
Confidential and Proprietary Information of  Oyster Point Pharma  
 
Reasonable possibility means that there is evidence to suggest a causal relationship 
between the drug and the AE.  
 Not Related – There is not a reasonable possibility that the a dministration of the drug 
caused the event, there is no temporal relationship between the drug and event onset, or 
an alternate etiology has been established.  
7.3.3.3  Expectedness  
The PI  will be responsible for determining whether an adverse event (AE) is expecte d or 
unexpected.  An AE will be considered unexpected if the nature, severity, or frequency of the 
event is not consistent with the risk information previously described for the drug. 
7.3.4 Time Period and Frequency for Event Assessment and Follow -Up 
Safety will be assessed by monitoring and recording potential adverse effects at each study visit. 
Participants will be monitored by medical histories  and physical examinations. If grading does 
not exist for an adverse event, the severity of mild, moderate, severe, li fe-threatening, and death, 
corresponding to Grades 1 -5, will be used whenever possible.  
At each contact with the subject, the investigator will seek information on adverse events by non -
directive questioning and, as appropriate, by examination. Adverse eve nts may also be detected 
when they are volunteered by the subject during the screening process or between visits, or 
through physical examination, laboratory test, or other assessments. Information on all adverse 
events will be recorded in the source docum entation. To the extent possible, adverse events will 
be recorded as a diagnosis and symptoms used to make the diagnosis recorded within the 
diagnosis event.  
As much as possible, each adverse event or follow -up information will be evaluated to 
determine:  
1. Severity grade (CTCAE Grade 1 -5) 
2. Duration (start and end dates)  
3. Relationship to the study treatment or process – [Reasonable possibility that AE is 
related: No (unrelated/ not suspected) or Yes (a suspected adverse reaction)]. If yes 
(suspected) - is the event possibly, probably or definitely related to the investigational 
treatment?  
4. Expectedness to study treatment or process – [Unexpected – if the event severity and/or 
frequency is not described in the investigator brochure (if applicable) or protocol].  
5. Action taken with respect to study or investigational treatment or process (none, dose 
adjusted, temporarily interrupted, permanently discontinued, unknown, not applicable)  
6. Whether medication or therapy taken (no concomitant medication/non -drug therapy, 
concomitant medication/non -drug therapy)  
  
Protocol 851655 - The SENSation Study   
OC-01 (varenicline solution) Nasal Spray  Page 42 of 67 
 
 
Confidential and Proprietary Information of  Oyster Point Pharma  
 
7. Whether the event is serious  
Once an adverse event is detected, it should be followed until its resolution or until it is judged to 
be permanent, and assessment should be made at each visit (or more frequently, if nece ssary) of 
any changes in severity, the suspected relationship to the study treatment, the interventions 
required to treat it, and the outcome.  
7.3.5 Adverse Event Reporting  
Reporting Period  
Adverse events will be reported from the time of informed consent until study completion.  
Investigator Reporting: Notifying the Study Sponsor  
Every SAE, regardless of suspected causality (e .g., relationship to study product (s) or study 
procedure (s) or disease progression) must be reported to the sponsor within 24 hours of learning 
of its occurrence.  
Recurrent episodes, complications, or progression of the initial SAE must be reported to the 
Sponsor as a follow -up to the original  episode within 24 hours of the investigator receiving the 
follow -up information. A SAE considere d completely unrelated to a previously reported one 
should be reported separately as a new event.  
Send the SAE report  to the PI. 
New information regarding the SAE will be reported as it becomes available and in the same 
manner that the initial SAE (i.e. SAE form ). The investigator must follow the event to resolution 
or until the event is deemed and documented irreversible, whichever is longer.  
Investigator  Reporting: Local Reporting Requirements  
The investigator will report AEs and SAEs to the  IRB/EC of rec ord and other local regulatory 
groups per the local requirements.  
7.3.6 Serious Adverse Event Reporting  
The study clinician will immediately report to the sponsor any serious adverse event, whether or 
not considered drug related, including those listed in the protocol or investigator brochure and 
must include an assessment of whether there is a reasonable possibility that the drug caused the 
event. Study endpoints that are serious adverse events (e.g., all -cause mortality ) must be reported 
in accordance with the protocol unless there is evidence suggesting a causal relationship between 
the drug and the event (e.g., death from anaphylaxis). In that case, the investigator must 
immediately report the event to the sponsor.  
New  information regarding the SAE will be reported as it becomes available and in the same 
manner that the initial SAE (i.e. SAE form). All serious adverse events (SAEs) will be followed 
until satisfactory resolution or until the site investigator deems the e vent to be chronic or the 
  
Protocol 851655 - The SENSation Study   
OC-01 (varenicline solution) Nasal Spray  Page 43 of 67 
 
 
Confidential and Proprietary Information of  Oyster Point Pharma  
 
participant is stable. Other supporting documentation of the event may be requested by the Data 
Coordinating Center (DCC)/study sponsor and should be provided as soon as possible.  
The SAE reports to the Sponsor should be sent to :  the study sponsor.  
The study sponsor will be responsible for notifying the FDA of any unexpected fatal or life -
threatening suspected adverse reaction per applicable regulation s. In addition, the sponsor must 
notify FDA , as applicable  and all participatin g investigators of potential serious risks, from 
clinical trials or any other source, as per the applicable regulation.  
7.3.7 Reporting Events to Participants  
AEs, SAs, and study -related results will be reported to participants on an aggregate level.  
7.3.8 Events of  Special Interest  
Not applicable.  
7.3.9 Reporting of Pregnancy  
Pregnancy, in and of itself, is not regarded as an AE unless there is suspicion that study drug or 
process may have interfered with the effectiveness of a contraceptive medication or method. 
When a  pregnancy has been confirmed in a subject , and the fetus is exposed to study drug and/or 
process  (maternally  or paternal ly), the following procedures should be followed to ensure subject 
safety:  
 Stopping the drug.  
Data on fetal outcome are collected for  regulatory reporti ng and drug safety evaluation. Follow -
up should be conducted for each pregnancy to determine outcome, including spontaneous or 
voluntary termination, details of the birth, and the presence or absence of any birth defects, 
congenital abno rmalities, or maternal and/or newborn complications.  
7.4 Unanticipated Problems  
7.4.1 Definition of Unanticipated Problems (UP)  
The Office for Human Research Protections (OHRP) considers unanticipated problems involving 
risks to participants or others to include, in  general, any incident, experience, or outcome that 
meets all the following criteria:  
 Unexpected in terms of nature, severity, or frequency given (a) the research procedures 
that are described in the protocol -related documents, such as the Institutional Re view 
Board (IRB) -approved research protocol and informed consent document; and (b) the 
characteristics of the participant population being studied;  
  
Protocol 851655 - The SENSation Study   
OC-01 (varenicline solution) Nasal Spray  Page 44 of 67 
 
 
Confidential and Proprietary Information of  Oyster Point Pharma  
 
 Related or possibly related to participation in the research (“possibly related” means there 
is a reasonable  possibility that the incident, experience, or outcome may have been 
caused by the procedures involved in the research); and  
 Suggests that the research places participants or others at a greater risk of harm (including 
physical, psychological, economic, or  social harm) than was previously known or 
recognized.  
7.4.2 Unanticipated Problem Reporting  
Unanticipated problems (UPs) such as:  
 Post-marketing withdrawal of a drug, device, or biologic used in a research protocol due 
to safety concerns.  
 FDA ban of a drug, device, or biologic used in a research protocol due to safety concerns.  
 Complaint of a participant when the complaint indicates unexpected risks, or the 
complaint cannot be resolved by the research team  
 Breach of confidentiality  
 Incarceration of a particip ant when the research was not previously approved under 
Subpart C and the investigator believes it is in the best interest of the subject to remain on 
the study  
 Premature closure of a study (e.g., due safety, lack of efficacy, feasibility, financial 
reason s, etc.)  
should be reported by the investigator to  the Sponsor, reviewing Institutional Review Board 
(IRB) and to the lead principal investigator (PI). The UP report will include the following 
information:  
 Protocol identifying information: protocol title a nd number, PI’s name, and the IRB 
project number;  
 A detailed description of the event, incident, experience, or outcome;  
 An explanation of the basis for determining that the event, incident, experienc e, or 
outcome represents an UP;  
 A description of any ch anges to the protocol or other corrective actions that have been 
taken or are proposed in response to the UP.  
To satisfy the requirement for prompt reporting, UPs will be reported  using the following 
timeline:  
 UPs that are serious adverse events (SAEs) will be reported as any other SAE.  
  
Protocol 851655 - The SENSation Study   
OC-01 (varenicline solution) Nasal Spray  Page 45 of 67 
 
 
Confidential and Proprietary Information of  Oyster Point Pharma  
 
 Any other UP will be reported to the  <Sponsor,  IRB and to the DCC/study sponsor 
within <insert timeline in accordance with SOP and policy> of the investigator  becoming 
aware of t he problem.  
 All UPs should be reported to appropriate institutional officials (as required by an 
institution’s written reporting procedures), the supporting agency head (or designee), and 
the Office for Human Research Protections (OHRP) within appropriate timeline  of the 
IRB’s receipt of the report of the problem from the investigator.  
7.4.3 Reporting Unanticipated Problems To Participants  
Unanticipated problems will be reported to participants on an aggregate level.  
7.5 Device Reporting  
Safety reporting for the de vice(s) will be according to 21 CFR 812.150.  
8 STATISTICAL CONSIDER ATIONS  
8.1 Statistical Hypotheses  
No formal sample size calculation will be made in this small directional signal seeking study. 
Demographic and baseline characteristics will be summarized descri ptively. Continuous 
variables will be summarized with mean, median, and standard deviation. Categorical variables 
will be summarized with frequency and percentage. Independent t tests will compare between the 
two groups and paired t tests to compare data b efore and after treatment within groups  
8.2 Sample Size Determination  
No formal sample size calculation will be made in this small directional signal seeking study.  
8.3 Populations for Analyses  
All participants will be included in the analysis.  
8.4 Statistical Analy ses 
8.4.1 General Approach  
Demographic and baseline characteristics will be summarized descriptively. Continuous 
variables will be summarized with mean, median, and standard deviation. Categorical variables 
will be summarized with frequency and percentage. Indep endent t tests will compare between the 
two groups and paired t tests to compare data before and after treatment within groups . 
8.4.2 Analysis of the Primary Efficacy Endpoint(s)  
Mean change in cornea and conjunctival staining from baseline to Day 28  
  
Protocol 851655 - The SENSation Study   
OC-01 (varenicline solution) Nasal Spray  Page 46 of 67 
 
 
Confidential and Proprietary Information of  Oyster Point Pharma  
 
Mean change  in eye dryness score as measured by the Visual Analogue Scale (VAS) from 
baseline to Day 28  
8.4.3 Analysis of the Secondary Endpoint(s)  
Mean change in best corrected visual acuity from baseline to Day 28  
Mean change in dry mouth and dry nose scale as measured by from baseline through Day 28  
Incidence and severity of adverse events  
8.4.4 Safety Analyses  
Summary statistics of adverse events will be presented in a table.  
8.4.5 Baseline Descriptive Statistics  
Demographic and baseline characteristics will be summarized descrip tively.  
8.4.6 Planned Interim Analyses  
Not applicable.  
8.4.7 Sub-Group Analyses  
Due to small sample size, sub -group analyses will not be performed.  
8.4.8 Tabulation of Individual Participant Data  
Individual participant data will not be tabulated.  
8.4.9 Exploratory Analyses  
Mean change in Muco -Aqueous layer thickness (MALT) and Lipid Map Uniformity (LMU) 
values from baseline to 15 minutes post treatment as measured by the Tear Film Imager 
masked reading center evaluation  
Mean change in Muco -Aqueous layer thickness (MALT) and Li pid Map Uniformity (LMU) 
values from baseline to Day 28 as measured by the Tear Film Imager masked reading center 
evaluation [Insert Text Here]  
  
Protocol 851655 - The SENSation Study   
OC-01 (varenicline solution) Nasal Spray  Page 47 of 67 
 
 
Confidential and Proprietary Information of  Oyster Point Pharma  
 
9 SUPPORTING DOCUMENTA TION AND OPERATIONAL  
CONSIDERATIONS  
9.1 Regulatory, Ethical, and Study Oversight Considerations  
9.1.1 Informed Consent Process  
9.1.1.1  Consent/Assent and Other Informational Documents Provided To Participants  
Consent forms describing in detail the drug, study procedures, and risks are given to the 
participant and written documentation of i nformed consent is required prior to starting 
intervention/administering drug. The following consent materials are submitted with  this 
protocol: consent form.  
9.1.1.2  Consent Procedures and Documentation  
Informed consent is a process that is initiated prior to the  individual’s agreeing to participate in 
the study and continues throughout the individual’s study participation. Consent forms will be 
Institutional Review Board (IRB) -approved and the participant will be asked to read and review 
the document. The investi gator will explain the research study to the participant and answer any 
questions that may arise. A verbal explanation will be provided in terms suited to the 
participant’s comprehension of the purposes, procedures, and potential risks of the study and of 
their rights as research participants.  Participants will have the opportunity to carefully review the 
written consent form and ask questions prior to signing. The participants should have the 
opportunity to discuss the study with their family or surrogates  or think about it prior to agreeing 
to participate. The participant will sign the informed consent document prior to any procedures 
being done specifically for the study. Participants must be informed that participation is 
voluntary and that they may with draw from the study at any time, without prejudice. A copy of 
the informed consent document will be given to the participants for their records. The informed 
consent process will be conducted and documented in the source document (including the date), 
and the form signed, before the participant undergoes any study -specific procedures. The rights 
and welfare of the participants will be protected by emphasizing to them that the quality of their 
medical care will not be adversely affected if they decline to pa rticipate in this study.  
9.1.2 Study Discontinuation and Closure  
This study may be temporarily suspended or prematurely terminated  by the Sponsor or the PI at 
any site  if there i s sufficient reasonable cause. Written notification, documenting the reason for 
study suspension or termination, will be provided by the suspending or terminating party to 
investigator and participants.  If the study is prematurely terminated or suspended, the Principal 
Investigator (PI) will promptly inform study participants, the Institutional Review Board (IRB), 
and sponsor and will provide the reason(s) for the termination or suspension.  Study participants 
will be contacted, as applicable, and be informed of changes to study visit schedule.  
  
Protocol 851655 - The SENSation Study   
OC-01 (varenicline solution) Nasal Spray  Page 48 of 67 
 
 
Confidential and Proprietary Information of  Oyster Point Pharma  
 
Circumstances that may warrant terminat ion or suspension include, but are not limited to:  
 Determination of unexpected, significant, or unacceptable risk to participants  
 Demonstration of efficac y that would warrant stopping  
 Insufficient compliance to protocol requirements  
 Data that are not suffi ciently complete and/or evaluable  
 Determination that the primary endpoint has been met  
 Determination of futility  
Study may resume once concerns about safety, protocol compliance, and data quality are 
addressed, and satisfy the sponsor, IRB and/or Food and Drug Administration (FDA).  
In terminating the study, the Sponsor and the Principal Investigator will assure that adequate 
consideration is given to the protection of the subjects’ interests.  
9.1.3 Confidentiality and Privacy  
Participant confidentiality and priva cy is strictly held in trust by the participating investigators, 
their staff, and the sponsor(s) and their interventions. This confidentiality is extended to cover 
testing of biological samples and genetic tests in addition to the clinical information rela ting to 
participants. Therefore, the study protocol, documentation, data, and all other information 
generated will be held in strict confidence. No information concerning the study or the data will 
be released to any unauthorized third party without prior written approval of the sponsor.  
All research activities will be conducted in as private a setting as possible.  
The study monitor, other authorized representatives of the sponsor, representatives of the 
Institutional Review Board (IRB), regulatory agencie s or pharmaceutical company supplying 
study product may inspect all documents and records required to be maintained by the 
investigator, including but not limited to, medical records (office, clinic, or hospital) and 
pharmacy records for the participants i n this study. The clinical study site will permit access to 
such records.  
The study participant’s contact information will be securely stored at each clinical site for 
internal use during the study. At the end of the study, all records will continue to be kept in a 
secure location for as long a period as dictated by the reviewing IRB, Institutional policies, or 
sponsor requirements.  
Study participant research data, which is for purposes of statistical analysis and scientific 
reporting, will be transmitted t o and stored at the <specify name of Data Coordinating Center>. 
This will not include the participant’s contact or identifying information. Rather, individual 
participants and their research data will be identified by a unique study identification number. 
The study data entry and study management systems used by clinical sites and by <specify name 
of Data Coordinating Center> research staff will be secured and password protected. At the end 
  
Protocol 851655 - The SENSation Study   
OC-01 (varenicline solution) Nasal Spray  Page 49 of 67 
 
 
Confidential and Proprietary Information of  Oyster Point Pharma  
 
of the study, all study databases will be de -identified and archive d at the <specify name of Data 
Coordinating Center>.  
9.1.4 Future Use of Stored Specimens and Data  
Data collected for this study will be analyzed and stored at the <specify name of Data 
Coordinating Center >. After the study is completed, the de -identified, arc hived data will be 
transmitted to and stored at the <specify name of Data Repository>, for use by other researchers 
including those outside of the study. Permission to transmit data to the <specify name of Data 
Repository> will be in cluded in the informed consent.  
There will be no biological samples stored.  
9.1.5 Safety Oversight  
Safety oversight will be under the direction of a Data and Safety Monitoring Board (DSMB) 
composed of individuals with the appropriate expertise . Members of the DSMB should be 
independent from the study conduct and free of conflict of interest, or measures should be in 
place to minimize perceived conflict of interest.  The DSMB will meet at least semiannually to 
assess safety and efficacy data on each arm of the study. The DS MB will operate under the rules 
of an approved charter that will be written and reviewed at the organizational meeting of the 
DSMB. At this time, each data element that the DSMB needs to assess will be clearly defined. 
The DSMB will provide its input to the st udy sponsor.  
9.1.6 Clinical Monitoring  
Clinical site monitoring is conducted to ensure that the rights and well -being of trial participants 
are protected, that the reported trial data are accurate, complete, and verifiable, and that the 
conduct of the trial is in compliance with the currently approved protocol/amendment(s), with 
International Conference on Harmonisation Good Clinical Practice (ICH GCP), and with 
applic able regulatory requirement(s).  
9.1.7 Quality Assurance and Quality Control  
All monitoring and audits  are to be performed according to ICH GCP E6(R2).  
Each clinical site will perform internal quality management of study conduct, data and biological 
specimen collection, documentation and comp letion. An individualized quality management plan 
will be develop ed to descri be a site’s quality management.   
Quality control (QC) procedures will be implemented beginning with the data entry system and 
data QC checks that will be run on the database will be generated. Any missing data or data 
anomalies will be communic ated to the site(s) for clarification/resolution.  
Following written Standard Operating Procedures (SOPs), the monitors will verify that the 
clinical trial is conducted and data are generated , and specimens are collected, documented 
(recorded), and reported in compliance with the protocol, International Conference on 
  
Protocol 851655 - The SENSation Study   
OC-01 (varenicline solution) Nasal Spray  Page 50 of 67 
 
 
Confidential and Proprietary Information of  Oyster Point Pharma  
 
Harmonisation Good Clinical Practice (ICH GCP), and applicable regulatory requirements (e.g., 
Good Laboratory Practices (GLP), Go od Manufacturing Practices (GMP)).  
The investigational site will provide direct access to all trial related sites, source data/documents, 
and reports for the purpose of monitoring and auditing by the sponsor, and inspection by local 
and regulatory authorit ies. 
9.1.8 Data Handling and Record Keeping  
9.1.8.1  Data Collection and Management Responsibilities  
Data collection is the responsibility of the clinical trial staff at the site under the supervision of 
the site investigator. The investigator is responsible for ensuri ng the accuracy, completeness, 
legibility, and timeliness of the data reported.  
All source documents should be completed in a neat, legible manner to ensure accurate 
interpretation of data  and follow ALCOAC standards (attributable, legible, contemporaneous , 
original, accurate, and complete) . 
Hardcopies of the study visit worksheets will be provided for use as source document worksheets 
for recording data for each participant enrolled in the study.  Data recorded in the electronic case 
report form (eCRF) deri ved from source documents should be consistent with the data re corded 
on the source documents.  
Clinical data (including adverse events (AEs), concomitant medications, and expected adverse 
reactions data) and clinical laboratory data will be entered into <s pecify name of data capture 
system>, a 21 CFR Part 11 -compliant data capture system provided by the <specify Data 
Coordinating Center>. The data system includes password protection and internal quality checks, 
such as automatic range checks, to identify da ta that appear inconsistent, incomplete, or 
inaccurate. Clinical data will be entered directly from the source documents.]  
If using the Penn CTMS, the following text may be included:  
[Clinical and laboratory data will be entered into a 21 CFR Part 11-compliant electronic data 
capture system (EDC) that includes individual user account level password protection. This EDC 
(Velos version 9) supports programmable data entry validation rules and edit checks to identify 
data entry errors. ] 
9.1.8.2  Study Records R etention  
Study documents should be retained for a minimum of 2 years after the last approval of a 
marketing application in an International Conference on Harmonization  (ICH) region and until 
there are no pending or contemplated marketing applications in a n ICH region or until at least 2 
years have elapsed since the formal discontinuation of clinical development of the drug. These 
documents should be retained for a longer period, however, if required by local regulations. No 
records will be destroyed withou t the written consent of the sponsor, if applicable. It is the 
  
Protocol 851655 - The SENSation Study   
OC-01 (varenicline solution) Nasal Spray  Page 51 of 67 
 
 
Confidential and Proprietary Information of  Oyster Point Pharma  
 
responsibility of the sponsor to inform the investigator when these documents no longer need to 
be retained.  
9.1.9 Protocol Deviations  
The PI and the study team should document all scenarios where th e protocol is not followed and 
provide, in particular:  
 Who deviated from the protocol  
 What was the deviation  
 When did the deviation occur  
 How did the deviation happen  
 What is the impact of the deviation  
 A root cause analysis of why the deviation occurred  
If the assessment results in a determination that any of the following are potentially affected, the 
deviation would be considered of significant impact:  
 having the potential to adversely affect subject safety; OR  
 increases risks to participants; OR  
 adver sely affects the integrity of the data; OR  
 violates the rights and welfare of participants, OR  
 affects the subject’s willingness to participate in research.  
 there is a potential for an overall impact on the research that should be shared with the 
IRB for consideration and development of next best steps to address it  
 
9.1.10  Publication and Data Sharing Policy  
This study will c omply with the data sharing agreement . 
The Sponsor must approve all sharing of information/data prior to its occurrence.  
9.1.11  Conflict of Interest Policy  
The independence of this study from any actual or perceived influence, such as by the 
pharmac eutical industry, is critical. Therefore, any actual conflict of interest of persons who have 
a role in the design, conduct, analysis, publication, or any aspect of this trial will be disclosed 
and managed. Furthermore, persons who have a perceived conflic t of interest will be required to 
  
Protocol 851655 - The SENSation Study   
OC-01 (varenicline solution) Nasal Spray  Page 52 of 67 
 
 
Confidential and Proprietary Information of  Oyster Point Pharma  
 
have such conflicts managed in a way that is appropriate to their participation in the des ign and 
conduct of this trial.  
9.2 Additional Considerations  
Not applicable.  
9.3 Protocol Amendment History  
 
Version  Date  Description of Change  Brief Rationale  
V.2 24Apr2023  Inclusion/Exclusion and Procedure 
Changes  Error in previous protocol  
    
    
    
    
    
    
    
    
    
 
10 REFERENCES  
Abelson, R., K. J. Lane, J. Rodriguez, P. Johnston, E. Angjeli, G. Ousler and D. Montgomery 
(2012). "A single -center study evaluating the effect of the controlled adverse environment 
(CAE(SM)) model on tear film stability." Clin Ophthalmol  6: 1865 -1872.  
Albrecht, J., R. Kopietz, J. Linn, V. Sakar, A. Anzinger, T. Schreder, O. Pollatos, H. Bruckmann, 
G. Kobal and M. Wiesmann (2009). "Activation of olfactory and trigeminal cortical areas 
following stimulation of the nasal mucosa with low con centrations of S( -)-nicotine vapor --an 
fMRI study on chemosensory perception." Hum Brain Mapp  30(3): 699 -710. 
 
Alimohammadi, H. and W. L. Silver (2000). "Evidence for nicotinic acetylcholine receptors on 
nasal trigeminal nerve endings of the rat." Chem Sen ses 25(1): 61 -66. 
  
Protocol 851655 - The SENSation Study   
OC-01 (varenicline solution) Nasal Spray  Page 53 of 67 
 
 
Confidential and Proprietary Information of  Oyster Point Pharma  
 
Belmonte C, Aracil A, Acosta MC, et al. Nerves and sensations from the eye surface. Ocul Surf  
2004; 2(4):248 –253. 
 
Barendregt PJ, van den Bent MJ, van Raaij -van den Aarssen VJ, et al. Involvement of the 
peripheral nervous system in prima ry Sjo¨gren’s syndrome. Ann Rheum Dis 2001;60(9):876 –
881. 
 
Farhangi M, Cheng AM, Baksh B, et alEffect of non -invasive intranasal neurostimulation on tear 
volume, dryness and ocular painBritish Journal of Ophthalmology 2020;104:1310 -1316.  
 
Feng Y, Simpson T L. Nociceptive sensation and sensitivity evoked from human  
 
Flores, C. M., R. M. DeCamp, S. Kilo, S. W. Rogers and K. M. Hargreaves (1996). "Neuronal 
nicotinic receptor expression in sensory neurons of the rat trigeminal ganglion: demonstration of 
alpha3b eta4, a novel subtype in the mammalian nervous system." J Neurosci  16(24): 7892 -7901.  
 
Gupta, A., T. Heigle and S. C. Pflugfelder (1997). "Nasolacrimal stimulation of aqueous tear 
production." Cornea  16(6): 645 -648. 
 
Han HC, Lee DH, Chung JM. Characteristics of ectopic discharges in a rat neuropathic pain 
model. Pain 2000; 84(2 -3):253 –261. 
 
Heigle, T. J. and S. C. Pflugfelder (1996). "Aqueous tear production in patients with 
neurotrophic keratitis." Cornea  15(2): 135 -138. 
 
Hurst, R., H. Rollema  and D. Bertrand (2013). "Nicotinic acetylcholine receptors: from basic 
science to therapeutics." Pharmacol Ther  137(1): 22 -54. 
 
 
Jensen TS, Baron R, Haanpa¨a¨ M, et al. A new definition of neuropathic pain. Pain 
2011;152(10):2204 –2205.  
 
Lee, L. Y., N. K. Burki, D. C. Gerhardstein, Q. Gu, Y. R. Kou and J. Xu (2007). "Airway 
irritation and cough evoked by inhaled cigarette smoke: role of neuronal nicotinic acetylcholine 
receptors." Pulm Pharmacol Ther  20(4): 355 -364. 
 
Liesegang TJ. Herpes zoster ophthalmicus  natural history, risk factors, clinical presentation, and 
morbidity. Ophthalmology 2008;115(2 suppl.):S3 –S12. 
 
Meerovitch, K., G. Torkildsen, J. Lonsdale, H. Goldfarb, T. Lama, G. Cumberlidge and G. W. 
Ousler, 3rd (2013). "Safety and efficacy of MIM -D3 ophthalmic solutions in a randomized, 
  
Protocol 851655 - The SENSation Study   
OC-01 (varenicline solution) Nasal Spray  Page 54 of 67 
 
 
Confidential and Proprietary Information of  Oyster Point Pharma  
 
placebo -controlled Phase 2 clinical trial in patients with dry eye." Clin Op hthalmol  7: 1275 -
1285.  
 
Morales -Perez, C. L., Noviello, C. M., & Hibbs, R. E. (2016). X -ray structure of the human α4β2 
nicotinic receptor.  Nature , 538(7625), 411.  
 
Mundorf, T., K. A. Wilcox, G. W. Ousler, 3rd, D. Welch and M. B. Abelson (2003). "Evaluatio n 
of the comfort of Alphagan P compared with Alphagan in irritated eyes." Adv Ther  20(6): 329 -
336. 
 
Oaklander AL. The density of remaining nerve endings in human skin with and without 
postherpetic neuralgia after shingles. Pain 2001;92(1 –2):139 –145. 
Wall P D, Gutnick M. Properties of afferent nerve impulses originating from a neuroma. Nature 
1974a; 248(5451): 740 –743. 
 
Ousler, G. W., 3rd, M. B. Abelson, L. A. Nally, D. Welch and J. S. Casavant (2002). "Evaluation 
of the time to "natural compensation" in norm al and dry eye subject populations during exposure 
to a controlled adverse environment." Adv Exp Med Biol  506(Pt B): 1057 -1063.  
 
Ousler, G. W., P. J. Gomes, D. Welch and M. B. Abelson (2005). "Methodologies for the study 
of ocular surface disease." Ocul Su rf 3(3): 143 -154. 
 
Özyol P, Özyol E, Karel F. Biocompatibility of Intraocular Lenses. Turk J Ophthalmol. 2017 
Aug;47(4):221 -225. doi: 10.4274/tjo.10437. Epub 2017 Aug 15. PMID: 28845327; PMCID: 
PMC5563551.  
 
Patane, M. A., A. Cohen, S. From, G. Torkildsen, D. Welch and G. W. Ousler, 3rd (2011). 
"Ocular iontophoresis of EGP -437 (dexamethasone phosphate) in dry eye patients: results of a 
randomized clinical trial." Clin Ophthalmol  5: 633 -643. 
 
Petrov, A., N. Per ekhvatova, M. Skulachev, L. Stein and G. Ousler (2016). "SkQ1 Ophthalmic 
Solution for Dry Eye Treatment: Results of a Phase 2 Safety and Efficacy Clinical Study in the 
Environment and During Challenge in the Controlled Adverse Environment Model." Adv Ther  
33(1): 96 -115. 
 
Pfizer, I. (2010). Nicotrol NS (nicotine nasal spray): Prescribing information..  
 
Pflugfelder, S. C., S. C. Tseng, K. Yoshino, D. Monroy, C. Felix and B. L. Reis (1997). 
"Correlation of goblet cell density and mucosal epithelial membrane mu cin expression with rose 
bengal staining in patients with ocular irritation." Ophthalmology  104(2): 223 -235. 
 
  
Protocol 851655 - The SENSation Study   
OC-01 (varenicline solution) Nasal Spray  Page 55 of 67 
 
 
Confidential and Proprietary Information of  Oyster Point Pharma  
 
Philip, G., F. M. Baroody, D. Proud, R. M. Naclerio and A. G. Togias (1994). "The human nasal 
response to capsaicin." J Allergy Clin Immunol  94(6 Pt 1): 1035 -1045.  
 
Razantsev, S. V., K. A. Nikitin and N. A. Russkikh (1992). "[Diagnostic significance of the 
study of lacrimal secretion in otorhinolaryngology]." Vestn Otorinolaringol (2): 14 -16. 
 
Robinson, S. R. and P. J. Wormald (2006). "Endoscopic vid ian neurectomy." Am J Rhinol  20(2): 
197-202. 
 
Schaumberg, D. A., R. Dana, J. E. Buring and D. A. Sullivan (2009). "Prevalence of dry eye 
disease among US men: estimates from the Physicians' Health Studies." Arch Ophthalmol  
127(6): 763 -768. 
 
Schaumberg, D. A., D. A. Sullivan and M. R. Dana (2002). "Epidemiology of dry eye 
syndrome." Adv Exp Med Biol  506(Pt B): 989 -998. 
 
Schaumberg, D. A., D. A. Sullivan, J. E. Buring and M. R. Dana (2003). "Prevalence of dry eye 
syndrome among US women." Am J Ophthalmol  136(2): 318 -326. 
 
Schaumberg, D. A., R. Dana, J. E. Buring and D. A. Sullivan (2009). "Prevalence of dry eye 
disease among US men: estimates from the Physicians' Health Studies." Arch Ophthalmol  
127(6): 763 -768. 
 
Semba, C. P., G. L. Torkildsen, J. D. Lonsdale, E. B. McLaurin, J. A. Geffin, T. K. Mundorf, K. 
S. Kennedy and G. W. Ousler (2012). "A phase 2 randomized, double -masked, placebo -
controlled study of a novel integrin antagonist (SAR 1118) for the treatment of dry eye." Am J 
Ophthalmol  153(6): 1050 -1060 e1051.  
 
Sheppard, J. D., G. L. Torkildsen, J. D. Lonsdale, F. A. D'Ambrosio, Jr., E. B. McLaurin, R. A. 
Eiferman, K. S. Kennedy, C. P. Semba and O. -S. Group (2014).  
"Lifitegrast ophthalmic solution 5.0% for treatment of dry eye disease: resu lts of the OPUS -1 
phase 3 study." Ophthalmology  121(2): 475 -483. 
 
 
Sosne, G. and G. W. Ousler (2015). "Thymosin beta 4 ophthalmic solution for dry eye: a 
randomized, placebo -controlled, Phase II clinical trial conducted using the controlled adverse 
environment (CAE) model." Clin Ophthalmol  9: 877 -884. 
 
Stapleton et al. (2 007). "The epidemiology of dry eye disease: report of the Epidemiology 
Subcommittee of the International Dry Eye WorkShop (2007)." Ocul Surf  5(2): 93 -107.  
 
  
Protocol 851655 - The SENSation Study   
OC-01 (varenicline solution) Nasal Spray  Page 56 of 67 
 
 
Confidential and Proprietary Information of  Oyster Point Pharma  
 
Stapleton, J. A. and G. Sutherland (2011). "Treating heavy smokers in primary care with the 
nicotin e nasal spray: randomized placebo -controlled trial." Addiction  106(4): 824 -832. 
 
Tauber, J., P. Karpecki, R. Latkany, J. Luchs, J. Martel, K. Sall, A. Raychaudhuri, V. Smith, C. 
P. Semba and O. -. Investigators (2015). "Lifitegrast Ophthalmic Solution 5.0% versus Placebo 
for Treatment of Dry Eye Disease: Results of the Randomized Phase III OPUS -2 Study." 
Ophthalmology  122(12): 2423 -2431.  
 
Thuerauf N, K. Markovic, G. Braun, S. Bleich, U. Reulbach, J. Kornhuber and J. Lunkenheimer 
(2006). "The influence of mec amylamine on trigeminal and olfactory chemoreception of 
nicotine." Neuropsychopharmacology  31(2): 450 -461. 
 
Tsubota, K. (1991). "The importance of the Schirmer test with nasal stimulation." Am J 
Ophthalmol  111(1): 106 -108. 
 
Tsubota, K., M. Yamada and K. Ur ayama (1994). "Spectacle side panels and moist inserts for the 
treatment of dry -eye patients." Cornea  13(3): 197 -201. 
 
Wall PD, Gutnick M. Ongoing activity in peripheral nerves: the physiology and pharmacology of 
impulses originating from a neuroma. Exp Neurol 1974b;43(3):580 –593. 
 
Walt JG, R. M., Stern KL (1997). "Evaluating the functional impact of dry eye: the Ocular 
Surface Disease Index [abstract]." Drug In J 31: 1436.  
 
11 APPENDIX  
11.1  Schedule of Activities (SoA)  
 
Study Procedure  Screening/  
Baseline  
(Visit 1)  15 minutes  
Post-
administration   
 
Visit 2   
 
Visit 3  
 Early  
Terminatio
n 
 Day -0 Day 0  Day 14 
(Virtual)  Day 28   
  
Protocol 851655 - The SENSation Study   
OC-01 (varenicline solution) Nasal Spray  Page 57 of 67 
 
 
Confidential and Proprietary Information of  Oyster Point Pharma  
 
Windows for Visits     +/- 2 days  +/- 7 days  
Informed Consent  X     
Demographics  X     
Medical History and 
Concurrent Illnesses  X  X X X 
Ocular History  X  X X X 
Eligibility Criteria  X     
Urine Pregnancy 
Test*  X   X X 
Concomitant 
Medications  X  X X X 
Intranasal Exam via 
history  X     
Eye Dryness Score 
(0-100) as measured 
by Visual Analogue 
Scale (VAS)  X  
X X X 
Nasal Dryness 
Score (0 -100) as 
measured by VAS  X  
X X X 
Dry Mouth Score 
(0-100) as measured 
by VAS  X  
X X X 
QIDS -SR 
Questionnaire  X  X X X 
Tear Film Imager 
(obtain tear film 
thickness)  X X  X  
(15 mins post 
treatment)  X 
Slit Lamp 
Biomicroscopy  X   X X 
Corneal Staining 
using NEI scale & 
Conjunctival 
Staining using Van 
Bijsterveld and 
Utrecht scale  X  
 X X 
Schirmer’s Test 
without anesthesia  X   X X 
Tear sample 
Collection  X   X X 
  
Protocol 851655 - The SENSation Study   
OC-01 (varenicline solution) Nasal Spray  Page 58 of 67 
 
 
Confidential and Proprietary Information of  Oyster Point Pharma  
 
 
 
  Ophthalmic 
Examination (w/or 
w/o dilated fundus 
exam)  X  
   
Dispense Study 
Product  X     
Collect Study 
Product     X X 
Adverse Events  X  X X X 
*For women of childbearing potential  
  
Protocol 851655 - The SENSation Study   
OC-01 (varenicline solution) Nasal Spray  Page 59 of 67 
 
 
Confidential and Proprietary Information of  Oyster Point Pharma  
 
APPENDICES  
 
Appendix I: Visual Analogue Scale  
 
 
 Eye Dryness Score (EDS) Using a Visual Analog Scale (VAS)  
The participant will be asked  to rate their ocular symptoms (both eyes simultaneously) due to eye 
dryness by placing a vertical mark on the horizontal line to indicate the level of discomfort; 0 
corresponds to “no discomfort” and 100 corresponds to “maximal discomfort.” The assessment  
line length of the scale will be 100 mm.  
Please rate your current eye dryness by drawing a vertical line on the line below:  
     
                                                 
  
 
 
 
The EDS is an instrument that has been used in other studies. (Sheppard, Torkildsen et al. 2014, 
Tauber, Karpecki et al. 2015)    
 
Please rate your current nose d ryness by drawing a vertical line on the line below:  
     
                                                 
  
No 
Discomfort  Maximal 
Discomfort  
  
Protocol 851655 - The SENSation Study   
OC-01 (varenicline solution) Nasal Spray  Page 60 of 67 
 
 
Confidential and Proprietary Information of  Oyster Point Pharma  
 
 
 
Please rate your current mouth dryness by drawing a vertical line on the line below:  
     
                                                 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Appendix II: QIDS -SR Questionnaire  No 
Discomfort  Maximal 
Discomfort  
No 
Discomfort  Maximal 
Discomfort  
  
Protocol 851655 - The SENSation Study   
OC-01 (varenicline solution) Nasal Spray  Page 61 of 67 
 
 
Confidential and Proprietary Information of  Oyster Point Pharma  
 
 
The Quick Inventory of Depressive Symptomatology (16 -Item) (Self -Report) (QIDS -SR16) 
Pg. 1 of 2  
 Name  or ID:  Date:     
 
CHECK  THE ONE  RESPONSE  TO EACH  ITEM  THAT  BEST  DESCRIBES  YOU  FOR  THE PAST  SEVEN  DAYS.  
During  the past seven days...  During  the past seven  days...  
1. Falling  Asleep:  
0 I never  take longer  than 30 minutes  to fall asleep.  
1 I take  at least  30 minutes  to fall asleep,  less than 
half the time.  
 
2 I take at least 30 minutes  to fall asleep,  more  than 
half the time.  
3 I take more  than 60 minutes  to fall asleep,  more  than 
half the time.  
 
2. Sleep  During  the Night  
0 I do not wake  up at night.  
1 I have  a restless,  light sleep  with a few brief 
awakenings  each  night.  
2 I wake  up at least  once  a night,  but I go back  to 
sleep  easily.  
3 I awaken more than once a night and stay awake  
for 20 minutes  or more,  more  than half the time.  
 
3. Waking  Up Too Early:  
 
0 Most  of the time,  I awaken  no more  than 30 minutes  
before  I need  to get up. 
1 More  than half the time,  I awaken  more  than 30 
minutes  before  I need  to get up. 
2 I almost always awaken at least one hour or so  
before  I need  to, but I go back to sleep  eventually.  
3 I awaken  at least  one hour before  I need  to, and 
can't go back  to sleep.  
 
4. Sleeping Too Much:  
0 I sleep  no longer  than 7-8 hours/night,  without  
napping  during  the day. 
1 I sleep  no longer  than 10 hours  in a 24-hour period  
including  naps.  
2 I sleep  no longer  than 12 hours  in a 24-hour period  
including  naps.  
3 I sleep  longer  than 12 hours  in a 24-hour period  
including  naps.  
 
 
 
 5. Feeling Sad:  
0 I do not feel sad. 
1 I feel sad less than half the time.  
2 I feel sad more  than half the time.  
3 I feel sad nearly  all of the time.  
Please complete  either  6 or 7 (not both)  
6. Decreased  Appetite:  
0 There  is no change  in my usual  appetite.  
1 I eat somewhat  less often  or lesser  amounts  of food than 
usual.  
2 I eat much  less than usual  and only with personal  effort.  
3 I rarely eat within a 24 -hour period, and only with  
extreme  personal  effort  or when  others  persuade  me to 
eat. 
- OR - 
7. Increased  Appetite:  
0 There  is no change  from my usual  
appetite.  
1 I feel a need  to eat more  frequently  than usual.  
2 I regularly  eat more  often  and/or  greater  amounts  of 
food than usual.  
3 I feel driven  to overeat  both at mealtime  and between  
meals.  
Please complete  either  8 or 9 (not both)  
8. Decreased  Weight  (Within  the Last Two Weeks):  
0 I have  not had a change  in my weight.  
1 I feel as if I have  had a slight  weight  loss. 
2 I have  lost 2 pounds  or more.  
3 I have  lost 5 pounds  or more.  
- OR - 
9. Increased Weight  (Within  the Last Two  Weeks):  
0 I have  not had a change  in my weight.  
1 I feel as if I have  had a slight  weight  gain.  
2 I have  gained  2 pounds  or more.  
3 I have  gained  5 pounds  or more.  
 
  
Protocol 851655 - The SENSation Study   
OC-01 (varenicline solution) Nasal Spray  Page 62 of 67 
 
 
Confidential and Proprietary Information of  Oyster Point Pharma  
 
 
 
 
 
 
During  the past seven days...  During  the past seven  days...  
10. Concentration  / Decision  Making:  14. Energy  Level:  
0 There  is no change  in my usual  capacity  to 
concentrate  or make  decisions.  
1 I occasionally  feel indecisive  or find that my attention  
wanders.  
2 Most  of the time,  I struggle  to focus  my attention  or 
to make  decisions.  0 There  is no change  in my usual  level of energy.  
1 I get tired more  easily  than usual.  
2 I have  to make  a big effort  to start or finish  my usual  daily 
activities  (for example,  shopping,  homework,  cooking,  or 
going  to work).  
3 I cannot  concentrate  well enough  to read or cannot  
make  even  minor  decisions.  
 
11. View  of Myself:  3 I really  cannot  carry  out most  of my usual  daily activities  
because  I just don't  have  the energy.  
 
15. Feeling  Slowed  Down:  
 
0 I see myself  as equally  worthwhile  and deserving  as 
other  people.  
1 I am more  self-blaming  than usual.  
2 I largely  believe  that I cause  problems  for others.  0 I think,  speak,  and move  at my usual  rate of speed.  
1 I find that my thinking  is slowed  down  or my voice  
sounds  dull or flat. 
2 It takes  me several  seconds  to respond  to most  
questions  and I'm sure my thinking  is slowed.  
3 I think  almost  constantly  about  major  and minor  
defects  in myself.  3 I am often  unable  to respond  to questions  without  
extreme  effort.  
 
12. Thoughts  of Death  or Suicide:  16. Feeling  Restless:  
0 I do not think  of suicide  or death.  
1 I feel that life is empty  or wonder  if it's worth  living.  
2 I think  of suicide  or death  several  times  a week  for 
several  minutes.  0 I do not feel restless.  
1 I'm often  fidgety,  wringing  my hands,  or need  to shift 
how I am sitting.  
2 I have  impulses  to move  about  and am quite  restless.  
3 I think  of suicide  or death  several  times  a day in 
some detail, or I have made specific plans for  
suicide  or have  actually  tried to take my life. 3  At times,  I am unable  to stay seated  and need  to pace  
around.  
 
13. General  Interest  
0 There  is no change  from usual  in how interested  I 
am in other  people  or activities.  
1 I notice  that I am less interested  in people  or 
activities.  
2 I find I have  interest  in only one or two of my 
formerly  pursued  activities.  
3 I have  virtually  no interest  in formerly  pursued  
activities.  
  
Protocol 851655 - The SENSation Study   
OC-01 (varenicline solution) Nasal Spray  Page 63 of 67 
 
 
Confidential and Proprietary Information of  Oyster Point Pharma  
 
Appendix III: Tear Film Imager  
  
TFI quantifies the dynamic properties of the tear film inner layers  (muco -aqueous and lipid) 
using a single non -contact measurement  
 
Appendix IV: NEI Scale  
 
 
 
 

  
Protocol 851655 - The SENSation Study   
OC-01 (varenicline solution) Nasal Spray  Page 64 of 67 
 
 
Confidential and Proprietary Information of  Oyster Point Pharma  
 
Appendix IV: Van Bijsterveld and Utercht Scale  
 
 
Appendix VI: Schirmer’s Test with out Topical Anesthesia and Tear Collection  
 
Schirmer’s Strips with out Topical Anesthesia:  
2. Instruct the participant to keep the eyes gently closed for one minute.     
3. After opening the eyes and allowing the eyes to recover for approximately one additional 
minute, remove the excess moisture in the inferior fornix with a spear.   
4. Place Schirmer’s strips (35 mm x 5 mm size filter paper strip) in each eye at the junction 
of the middle and lateral thirds of the lower eye lid.    
5. Under ambient light, instruct the participant to look forward and to blink normally during 
the course of the test. The test s hould be performed in a room with no direct air  or 
sunlight  on the participant’s face.   
6. The Schirmer’s strips should remain in place until five minutes have elapsed or both 
strips have reached maximum score.   
7. After five minutes, remove the Schirmer strips from both eyes and record the amount of 
wetting.  
8. Use forceps to hold the strip and cut 2 -3mm above the tear migration line (dye line) and 
place into the collection tube.  
9. Place one strip into each of the collection tubes that were provided.  On the label, please 
indicate if it is Right or Left eye (R = right and L = left) next to the subject ID (ex: 115 -
001-R; 115 -001-L).  Place the label on the applicable collection tube.  
 
 Kit Content:  
 2 Collection Tubes (Eppendorf Tubes)  
 2 Schirmer’s Strips  
 2 Labels (on e for each tube)  
 
Schirmer’s test and collection  
Once both strips have been placed into their own labeled vial, insert both vials back into the 
labeled collection kit box and store at -20C until further instructions for shipment.  

  
Protocol 851655 - The SENSation Study   
OC-01 (varenicline solution) Nasal Spray  Page 65 of 67 
 
 
Confidential and Proprietary Information of  Oyster Point Pharma  
 
Samples may be batch shi pped.  Ship all samples overnight on Dry Ice  
  
Protocol 851655 - The SENSation Study   
OC-01 (varenicline solution) Nasal Spray  Page 66 of 67 
 
Confidential and Proprietary Information of Oyster Point Pharma  
 
 
 
 
 
 
END OF DOCUMEN T
  
Protocol 851655 - The SENSation Study   
OC-01 (varenicline solution) Nasal Spray  Page 67 of 67 
 
Confidential and Proprietary Information of Oyster Point Pharma  
 
 